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Abstract 
 
 Murine model organisms are an essential tool in the scientific community quest to 
decipher the molecular etiology of human diseases. Currently, several methods are 
used to induce or reproduce human diseases in mouse models using advanced genetic 
engineering techniques to mutate the wild-type genes. We utilized the Baygenomics 
gene-trap method to study the effects of two mammalian genes: FOXN3 and CHD2. 
The Forkhead Box (FOX) family of transcription factors shares a common DNA-binding 
domain and has been associated with organ development, differentiation, cell growth 
and proliferation, and cancer. Meanwhile, the CHD (Chromodomain helicase DNA 
binding protein) family of proteins is known to be involved in chromatin remodeling and 
regulation of gene expression. Phenotypic analysis of Foxn3 mutant animals revealed 
its indispensible role in craniofacial and embryonic development, embryonic lethality, 
expression of bone morphogenetic proteins, and spontaneous development of cancers 
in heterozygous and homozygous mutant mice. Preliminary evaluation of molecular 
mechanisms of FOXN3 signifies deregulation of cell-cycle checkpoint proteins Cyclin-B1 
and CDK2 as the underlying etiology of tumors. Chd2 mutant mice exhibit spontaneous 
thymic and splenic lymphomas and reduced lifespan which can be restored through 
Chd2 re-expression in the thymus. At the molecular level, CHD2 deficiency reduces 
Puma (p53-upregulated modulator of apoptosis) induction after DNA damage in mouse 
thymocytes and HCT116 cells. Additionally, CHD2 is enriched at the Puma locus after 
DNA damage. CHD2-deficient cells also exhibit global reduction of active transcription 




   
Table of Contents 
Chapter I .....................................................................................................................................1 
The Utilization of Animal Models to Study Genes in Development and Disease ..........................1 
Introduction to Model Organisms .............................................................................................1 
Non-mammalian Model Organisms .........................................................................................1 
Other non-mammalian organisms. .......................................................................................4 
Mammalian Model Organisms .................................................................................................5 
Methods for Inducing Human Disease. ....................................................................................7 
Large scale mutation screens. .............................................................................................7 
Transgenic mice...................................................................................................................8 
Knock-Out and Knock-In mice. .............................................................................................9 
Conditional gene modifications. .........................................................................................10 
Mouse Models for Tumorogenesis. ........................................................................................11 
Breast cancer models. .......................................................................................................12 
Colorectal cancer models. ..................................................................................................12 
Models for other cancer hallmarks. ....................................................................................13 
Chapter II ..................................................................................................................................15 
Eukaryotic Transcription Regulation, and The Forkhead Box Family of Proteins .......................15 
Introduction to Eukaryotic Transcription Regulation ...............................................................15 
Transcription Factors .............................................................................................................15 
Regulation of Transcription Factors .......................................................................................17 
Translation and nuclear localization ...................................................................................17 
Activation signals ...............................................................................................................18 
Transcriptional regulatory complexes .................................................................................19 
Transcription Factors and Signaling Pathways ......................................................................20 
Superclass Helix-turn-Helix ...................................................................................................22 
The Forkhead Box .................................................................................................................24 
FOX crystal structure and phylogeny .................................................................................25 
FOX proteins and development ..........................................................................................26 
FOX proteins and transcription ...........................................................................................27 
FOXN Subfamily ................................................................................................................29 
FOXN3 (Checkpoint Suppressor 1) ....................................................................................31 
Foxn3 mouse model ..........................................................................................................34 
 
   
Materials and Methods ..........................................................................................................36 
Polymerase Chain Reaction (PCR) ....................................................................................36 
PRIMERS ..........................................................................................................................37 
Micro Computed Tomography (mCT) Image analysis ........................................................38 
RNA isolation and RT-PCR protocol ..................................................................................38 




Role of Foxn3 in Mammalian Development ........................................................................53 
Expression Analysis of Foxn3 in Developing Embryo .........................................................55 
Craniofacial Development and FOXN3 ..............................................................................58 
Correlation of Foxn3 and Human Disease..........................................................................60 
Chapter III .................................................................................................................................61 
FOX Proteins, Cell-Cycle Regulation and Tumorgenesis ..........................................................61 
Previous studies on FOX proteins and cancer .......................................................................61 
FOXM family ......................................................................................................................62 
FOXO family ......................................................................................................................63 
FOXP family .......................................................................................................................64 
FOXN3 and cancer ............................................................................................................65 
Materials and Methods ..........................................................................................................66 
Generation of Foxn3 mutant mice ......................................................................................66 
Generation of Mouse Embryonic Fibroblasts. .....................................................................66 
Immortalization of Foxn3 MEFs ..........................................................................................66 
Clonogenicity Assay ...........................................................................................................67 
       RNA Interference Transfection…………………………………………………………………...72 
Western Blot ......................................................................................................................67 
Reagents and Antibodies ...................................................................................................68 
Statistical analyses and survival curves .............................................................................69 
Results ..................................................................................................................................70 
3.1. Characterization of tumorogenesis in Foxn3 mice .......................................................70 
3.2. Impaired DNA repair in Foxn3 deficient MEFs .............................................................72 
3.3. FOXN3 deficiency deregulates cell-cycle regulatory proteins ......................................74 
 
   
Discussion .............................................................................................................................75 
Chapter IV .................................................................................................................................79 
Chromatin Remodeling Proteins and The Role of CHD2 in Tumorgenesis ................................79 
Chromatin and Nucleosome Dynamics ..................................................................................79 
Histone modifying proteins ....................................................................................................80 
ATP-dependent chromatin remodeling factors .......................................................................82 
The CHD family of chromatin remodeling proteins .................................................................84 
CHD Subfamily I ................................................................................................................85 
CHD Subfamily II ...............................................................................................................87 
CHD Subfamily III ..............................................................................................................88 
Chromodomain Helicase DNA Binding Protein 2 (CHD2) ......................................................90 
Chd2 mouse models ..........................................................................................................91 
Materials and Methods ..........................................................................................................93 
Reagents and Antibodies ...................................................................................................93 
Western Blot ......................................................................................................................93 
RNA isolation and RT-PCR protocol ..................................................................................94 
Quantitative PCR ...............................................................................................................95 
Chromatin Immunoprecipitation .........................................................................................95 
       RNA Interference Transfection………………………………………………………………….101 
Results ..................................................................................................................................97 
4.1. Characterization of N-terminal Chd2 deficient mice. ....................................................97 
4.2. Chd2 deficient thymocytes exhibit deficient Puma response. .................................... 101 
4.3. CHD2 deficient cells exhibit reduced PUMA induction ............................................... 104 
4.4. CHD2 localizes to Puma in mouse thymocytes. ........................................................ 106 
4.5. CHD2 localizes to Puma in p53-dependent manner in HCT116 cells. ....................... 109 
Discussion ........................................................................................................................... 116 





   
List of Figures 
 
Figure 1. Schematic representation of the Baygenomics gene trap integrated into intron 3 
of Foxn3 gene...................................................................................................................35 
Figure 2. Schematic representation of the strategy utilized to configure the gene-trap 
insertion site in intron 3 of the Foxn3 gene. ..................................................................35 
Figure 3. PCR analysis of multiple forward primers of intron 3 of the Foxn3 gene.. .........41 
Figure 4. Schematic representation of the Foxn3 chromosome locus in wild type, 
heterozygous, and nullyzygous mice. ............................................................................42 
Figure 5. Schematic configuration of the FoxN3 gene. ........................................................44 
Figure 6. Expression analysis of Foxn3 during embryogenesis. ........................................46 
Figure 7. Photographs of FoxN3 WT and mutant mice at P8 and P11 showing the runting 
phenotype. ........................................................................................................................47 
Figure 8. Craniofacial skeletal developmental defects in Ches1 mutants.. ........................48 
Figure 9. Histological assessment of calvaria in 11 day old wild type (left) and 
homozygous mutant (right) littermates. .........................................................................49 
Figure 10.  Compound microscope images of 13.5 and 14.5 d.p.c. wildtype and null 
embryos.. ..........................................................................................................................50 
Figure 11. Reduced expression of osteogenic genes in Foxn3 mutant mice and cell lines..
 ..........................................................................................................................................52 
Figure 12. Survival Curve of Foxn3 mice. .............................................................................71 
Figure 13. Survival analysis of Foxn3-deficient mice after IR treatment. ............................72 
Figure 14. Clonogenicity assay of Foxn3 MEFs. ...................................................................73 
Figure 15. Western blot analysis of cell-cycle progression proteins after RNAi-mediated 
knockdown of FOXN3.. ....................................................................................................74 
Figure 16.Schematic representation of the Baygenomics gene trap integrated into intron 
1 of Chd2 gene.. ...............................................................................................................92 
Figure 17. Schematic representation of the strategy utilized to configure the gene-trap 
insertion site in intron 1 of the Chd2 gene. ....................................................................93 
Figure 18. Chd2 deficiency leads to reduced lifespan in mice. Kaplan-Meier survival 
curves of Chd2 mutant and wild-type littermates ..........................................................98 
Figure 19. Restoration of CHD2 expression in thymus restores normal life span of CHD2 
heterozygous mice. ....................................................................................................... 100 
 
   
Figure 20. Effects of Chd2 on Cell-cycle Arrest.. ................................................................ 101 
Figure 21. Expression of PUMA in Chd2 Thymocytes.   ..................................................... 102 
Figure 22. Real-Time analysis of PUMA levels in Chd2 thymocytes.  ............................... 103 
Figure 23. Western blot analysis of CHD2 deficient DNA-damage response in HCT116 
cells................................................................................................................................. 105 
Figure 24. Western blot analysis of CHD2 deficient DNA-damage response in HCT116 
cells................................................................................................................................. 106 
Figure 25. Chromatin immunoprecipitation (ChIP) on wildtype thymocytes. ................... 107 
Figure 26. Chromatin immunoprecipitation (ChIP) on wildtype thymocytes. ................... 108 
Figure 27. Chromatin Immunoprecipitation analysis on Chd2 Thymocytes. .................... 109 
Figure 28. Chromatin Immunoprecipitation analysis of CHD2 localization to p53 response 
element in Puma.. .......................................................................................................... 111 
Figure 29. ChIP analysis of p53 localization to its response element in Puma. ............... 112 
Figure 30. ChIP analysis of CHD2 localization to a 5KB region upstream of Puma 
promoter. ........................................................................................................................ 113 
Figure 31. ChIP analysis of CHD2 localization to an unrelated Beta-Glucuronidase 
promoter. ........................................................................................................................ 114 
Figure 32. ChIP analysis of Acetylated histone H3 (Lys9) localization to Puma promoter..




   
List of Tables 
Table 1. Embryonic and postnatal lethality of FoxN3 mutant mice.  ...................................45 
Table 2. Phenotype comparison of human patients with 14q deletions and FoxN3 mutant 
mice. .................................................................................................................................51 







The Utilization of Animal Models to Study Genes in Development and Disease 
Introduction to Model Organisms 
 A model organism is a class of living organisms extensively used to identify or 
perform in-depth studies on a biological process. Because many aspects of biology are 
similar in most or all organisms, it is typically easier to study a particular aspect of a 
biological process in one organism over the others. Selection of proper model organism 
to conduct research is of utmost importance; principal investigators must select the 
model organism depending on the echelon of biology pursued, as in macro- versus 
micro- biology. The most popular model organisms have strong advantages to perform 
experimental research, such as rapid development with short life cycles, small adult 
size, constant availability, ease of handling, and common usage by other scientists (1). 
Model organisms can be generally classified into three main categories: mammalian 
models, non-mammalian models, and plants. For this dissertation, we will focus heavily 
on mammalian models and some non-mammalian models; plant model organisms such 
as Arabidopsis thaliana will not be discussed. Non-mammalian model organisms 
include members of all three domains of modern taxonomy: Archaea, Bacteria, and 
Eukarya. Mammalian model organisms represent the Mammalia class within the 
Animalia kingdom of the Eukarya domain.  
Non-mammalian Model Organisms 
  Non-mammalian model organisms spread over the three domain of living 
organisms and vary greatly in tissue complexity and even cellular components. 
However, they are very advantageous to study fundamental cellular processes that are 
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inherently conserved in higher organisms. On genetic basis, our understanding of gene 
function is typically inferred by comparing the phenotypic consequences of mutating the 
canonical “wild-type” gene in one organism and relating this phenotype to mutants of 
orthologous genes in a different organism (2). One of the great advantages to using 
non-mammalian model organisms is the availability of whole-genome sequencing for 
many of these species, thus enabling scientists to compare genomic sequences and 
conservation of orthologous genes. Many scientists work on specific organisms or 
genus to uncover specialized processes; nevertheless, most scientists choose one of 
the NIH (National Institute of Health) supported model organisms. 
Escherichia coli. E. coli is a prokaryotic organism (Bacteria domain) widely used for 
basic scientific research. E. coli has been widely used to obtain basic biological 
processes including information on molecular biology and gene regulation, metabolic 
pathways and biochemistry (3). One of the major disadvantages to using a prokaryotic 
system is the lack of a nuclear membrane to compartmentalize the nucleus and 
transcriptional machinery. Nevertheless, the fast growth rate (0.5 hours / duplication) 
has made the utilization of prokaryotes for generating recombinant DNA and expressing 
recombinant proteins a tremendous asset for scientists. E. coli was used to synthesize 
human insulin through genetic engineering, and research utilizing E. coli remains active 
to find alternative energy resources (4).    
Saccharomyces cerevisiae. S. cerevisiae (baker‟s yeast, here forth referred to as 
yeast) is the simplest model organism of the Eukarya domain. Yeast is widely used to 
study basic eukaryotic cell biology and genetics, and the results obtained from these 
studies impact our understanding of cellular functions higher eukaryotes. The ease of 
3 
 
genetic manipulation of yeast and its genetic complexity allows scientists to analyze 
gene function (5). Yeast has been utilized to dissect an array of cellular functions 
ranging from replication, transcription, cell cycle regulation and mRNA splicing, to more 
complex processes such as cell signaling pathways, homologous recombination and G-
protein coupled receptors (6). Yeast has a fairly simplified genetic makeup (~4000 
genes) for eukaryotic organisms with rare horizontal transfer gain of genes or gene 
duplications (7).  
Caenorhabditis elegans. C. elegans is a small, free-living soil nematode (round 
worm) that has been used as the simplest multi-cellular eukaryotic organism. C. elegans 
has organ systems, complex sensory systems and shows coordinated behavior, thus 
making it a unique, yet simple animal to study at the embryological, neurobiological and 
cellular levels. C. elegans can be grown and genetically manipulated with the speed and 
ease of a micro-organism, making it a perfect organism to for genetic studies and 
genomic manipulation (8). Furthermore, C. elegans is transparent, which allows for 
visualization using a dissecting microscope to monitor cell movement. C. elegans has 
been at the forefront of small RNA research and their regulation of gene expression (9). 
Initial discovery of the first microRNAs (miRNA) and their function as regulators of gene 
expression was discovered in C. elegans. Moreover, double-stranded RNA-induced 
gene silencing and the current understanding of the RNA interference (RNAi) machinery 
were also first discovered in C. elegans (10). This discovery unveiled a new mechanism 
for gene regulation that is conserved in higher eukaryotes. Gene-function studies in C. 
elegans remain easiest for the simple model of delivering double stranded RNA through 
microinjecting the worm or feeding the worm bacteria that expresses the dsRNA.  
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Drosophila melanogaster. D. melanogaster, commonly known as the fruit fly, is one 
of the most commonly used organisms for classical and molecular genetics research. 
Use of Drosophila as a model organism is alluring for many reasons including its easy-
to-manipulate genetic system, relatively low cost and fast generation time, and 
biological complexity comparable to mammals (11). Many genes in the Drosophila 
genome have well conserved orthologues in mammals with highly conserved epigenetic 
mechanisms. Drosophila has been utilized to extensively study segmentation of its 
body plan and the control of homeotic genes in this segmentation (12). Embryology and 
development and oocyte polarity is another field where Drosophila has been used 
extensively to unravel the basic mechanisms behind these fundamental processes. 
Drosophila is also extensively used to study epigenetic transcriptional control, insulator 
functions, and chromatin modifications because of the ease of mapping of its polytene 
chromosome. Drosophila has long been used to study classical genetics and possess 
many unique genetic markers that are manifested in visible phenotypes that can be 
seen with the naked eye or under low-powered dissecting microscopes (12). The 
utilization of recessive balancer chromosomes along with genetic markers makes it 
easy to select for progeny with the desired homozygous mutation.      
Other non-mammalian organisms. Other NIH sponsored non-mammalian organisms 
include organisms from the Archea domain. Retroviruses, which are not classified as 
living organisms, are also sponsored organisms by NIH, as well as the parasites from 
the plasmodium genus, which cause malaria. Lastly, Dictyostelium discoideum 
(social amoeba) and Danio rerio (zebrafish) are the other non-mammalian model 
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organisms utilized in modern research laboratories for various studies including 
reproduction. 
Mammalian Model Organisms 
 Mammalian model organisms cover the mammalia class of the Animal kingdom 
and are heavily utilized in modern science to research and investigate human disease. 
Human subjects are not used for research purposes because of the obvious risk to life, 
except in highly regulated clinical trials. Therefore, animal models are employed in the 
study of human disease and they are chosen because of their similarity to humans on 
genetic, anatomical, and physiological basis (13). Experimental research of diseases is 
done on animal models because of their unlimited supply, ease of manipulation, and 
controlled settings. To obtain scientifically valid research, the conditions associated with 
an experiment must be closely controlled through manipulating only one variable while 
keeping all others constant. Scientists then monitor the consequences of changing the 
variable and record the observations to test their hypotheses. Since most experiments 
require an adequate number of subjects for testing, it is easier for scientists to use large 
numbers of animals to conduct their research. Animal models are used to study the 
genetic etiology of diseases, as well as diagnosis and treatments of such disease. 
Rodents are the most widely used NIH-sponsored mammalian model organisms due to 
their similar physiology to humans and high genomic homology; however some studies 
can use primates for more accurate studies of human diseases.  The two rodent models 
most used in scientific research are the mouse (Mus musculus) and the rat (Rattus 
norvegicus). For the purposes of this dissertation, we will focus on the mouse as a 
mammalian model organism to decipher gene functions.  
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Mus Musculus. The common house mouse is one of the most commonly used 
animals to study genetic principles and human disease. Humans and mice diverged 75 
million years ago, since then, their genomes have evolved and changed at a rate of 
nearly one substitution for every two nucleotides and by deletion and insertion 
mutations (14). Yet, ortholgous sequences can still be aligned to resemble the 
divergence and conservation of essential genes. The mouse genome is 14% smaller 
than the human genome in terms of euchromatic regions with 2.5Gb (19 autosomes, 1 
XY chromosomes) compared to 2.9 Gb (22 autosomes, 1 XY chromosomes) (14). The 
human genome has undergone expansion since the divergence of humans and mice 
with an overall ratio of 0.91 mouse/human locus span (measured in relative size of 
orthologous landmarks in the genome). The human gene catalogue predicts 27,049 
transcripts aggregated into 22,808 distinct predicted genes, while the mouse gene 
catalogue predicts 29,201 transcripts clustered in 22,011 distinct genes. Moreover, 80% 
of mouse genes have a strict 1:1 orthologue in humans, and the remaining genes 
belong to a gene family that has undergone expansion. This shows the high degree of 
homology between human and mouse genomes and the ability to correlate human and 
mouse gene functions. Since both genomes have been sequenced and comparative 
analysis of both genomes is established, the biomedical studies of human genes can be 
complemented by experimental manipulations of a corresponding mouse gene, allowing 
fast and reliable functional understanding of gene functions. In respect to the mouse 
genome, there are practical techniques for random mutagenesis along with hundreds of 
spontaneous mutations occurring in mice. However, the most important aspect of 
mouse biology is the ability to change the genome through transgenic, knockout and 
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knock-in techniques, allowing precise manipulation of the mouse genome (15). Thus, 
the utilization of mouse is unmatched as a model system for probing mammalian 
biology and human disease.   
Methods for Inducing Human Disease. 
 Despite similar genetic homology between humans and mice, replicating human 
disease conditions in mouse is complex due to the heterogeneity and outbred nature of 
human alleles compared to the inbred strains of mice. Many human congenital and 
developmental diseases are manifested as a result of chromosomal deletions and 
aberrations of alleles that can eliminate multiple genes within the region (16). Moreover, 
human diseases can be modified through single nucleotide polymorphisms (SNPs) and 
copy number variants (CNVs), affecting penetrance and responsiveness to treatments.  
Such studies are hard to duplicate in murine systems compared to modern reverse 
genetics approaches which have undertaken the majority of active research. These 
reverse genetics studies rely on various methods to interfere with gene function to study 
the phenotype and effect of this gene on homeostasis. Selection of proper interference 
method can ultimately affect the expressivity of the phenotype and the correlation of the 
model to human diseases; therefore, we will discuss some of the current methods used 
in creating genetically-modified mice.   
Large scale mutation screens. N-ethyl-N-nitrosourea (ENU) is an efficient mutagen 
used in the spermatogonia stem cells of mice to induce an array of different point 
mutations. The progeny mice can be identified based on alterations to the wild type 
phenotype and expansion of certain line based on the desired phenotype. On average, 
a mutation is predicted every 2.38 Mb of gene-encoding sequences and a functional 
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mutation is expected every 9.48 Mb, thus making mutagenesis dispersed and random  
(17). Although this technique is advantageous in generating multiple variable mutant 
progeny, there are disadvantages to this technique. First, it‟s difficult to establish the 
main causative mutation of the phenotype and requires multiple complementation 
crosses, and secondly, it‟s difficult to assess whether one gene mutation or two 
synergistic gene mutations contribute to the phenotype. One of the most successful 
ENU-generated and most utilized mouse models is the multiple intestinal neoplasia 
APC (ApcMin) mouse model, which was the first mouse model to recapitulate the human 
Familial Adenomatous Polyposis (FAP) disease (18). ApcMin mice are heterozygous for 
a germ-line mutation in Apc, and loss of heterozygosity due to somatic mutations 
renders the protein non-functional and activates the Wnt signaling pathway.   
 Other large scale mutations involve radiation induced (e.g. X-ray) chromosomal 
breaks and rearrangements (19). The main drawback to this mutagenesis system is the 
excessive gene translocations and deletions, and chromosomal rearrangements. On the 
other hand, this may simulate some human diseases where loci deletions and 
chromosome aberrations underlie the disease. IR-induced genomic instability is utilized 
as a method to induce cancers in mice mutant for DNA repair genes or any other gene 
to test the tumorogenic potential of the specific gene (20).   
Transgenic mice. Transgenic mice are generated by injecting foreign genetic material 
either directly into the fertilized egg through „pronuclear microinjection‟, or injecting the 
foreign DNA into nucleus of embryonic stem cells which are eventually injected into the 
blastocysts of a fertilized egg (21). The content of the foreign genetic material integrates 
into the genome of the embryo where it can modify the organism. Transgenic mice 
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expressing the exogenous Maloney leukemia virus were the first transgenic mice 
created (22). Transgenes have a powerful promoter (e.g. CMV) upstream of the coding 
sequence to drive efficient transcription of the gene. However, advancements of genetic 
engineering have made transgenic mice more useful in biomedical research. Tissue-
specific expression of exogenous genes has become a more useful model system that 
depends on cloning a tissue-specific gene promoter upstream of the exogenous gene 
construct (23). More recently, cloning a tamoxifen response element in the promoter of 
exogenous genes induces gene expression through intravenous injection of the 
hormone tamoxifen (24). However, the main drawback to transgene technology is that 
integration of the foreign DNA into the genome occurs at random, and the number of 
copies integrated varies. Therefore, transgene technology cannot be used to manipulate 
endogenous genes in a predetermined manner.  
Knock-Out and Knock-In mice. When a single gene is predetermined to trigger a 
specific disease, targeted mutagenesis of this gene is essential to elucidate molecular 
data of the etiology of the disease. Targeting a predetermined gene utilizes a molecular 
technique that is both cumbersome and inefficient: homologous recombination (HR) 
(19). The desired mutation is created through in-vitro gene targeting of Embryonic stem 
(ES) cells which are then microinjected into blastocysts and eventually a pseudo-
pregnant female for embryo development. The mutations in ES cells will be propagated 
through all tissue of the adult mouse after a series of crossings and selections based on 
coat color. In general, targeting of desired gene can result in „Knock-out‟ of gene 
resulting in loss of function in the null allele, gain of function through „Knock-in‟ of a 
transgene, or point mutation through exchange of an exon with a mutant exon. 
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Targeting vector or foreign DNA material typically carries characteristic sequences and 
markers for selection, in addition to the mutation of interest. Homologous recombination 
requires sequences that are similar to the target region of interest where strand 
exchange can take place (25). The vector also contains a neomycin resistance gene 
within the targeting vector to positively select for ES cells that have undergone 
recombination. A Thymine Kinase (TK) gene is found at in the targeting vector just 
outside the HR exchange region, whereby if a cell doesn‟t undergo proper HR, TK will 
be expressed and the ES cell will die. Although expensive, HR-mediated gene targeting 
has become the most effective way of studying genes and their role in diseases. 
Conditional gene modifications. HR mediated gene targeting sprung a new approach 
to targeting mutagenesis in mouse models. Since many genes are embryonic lethal if 
deleted, and many genes become inactivated in adults, a system that removes gene 
function at specific times or in adult organism became a more realistic rendition of 
human diseases (25). Scientists started targeting their genes by adding a flanking 
sequence termed „LoxP sites‟ in their targeting vectors, in addition to the original 
sequence of interest. Cre recombinase is an enzyme that recognizes these LoxP sites 
and floxes them (deletes the intervening DNA depending on their orientation), which 
often leads to deletion of an exon within the target gene. This creates a conditional gene 
knock-out phenotype that depends on the expression of the Cre recombinase enzyme. 
To add specificity to the system, Cre recombinase transgenic mice can be crossbred 
with knock-out mice to create mice with both features in their genome. Regulation of the 
Cre recombinase gene can be done at the promoter by adding a tissue-specific 
promoter that allows expression of Cre in a tissue specific lineage rather than whole 
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genome, thus targeting mutagenesis to the specified tissue. Additionally, a tamoxifen 
response element can be used in the Cre promoter, thus allowing floxing of the gene 
upon injection of estrogen to the bloodstream of mice (24).   
Mouse Models for Tumorogenesis.  
 There are many paradigms that underscore the translational efficacy of mouse 
models in understanding human disease. Despite having a high degree of genetic 
homology between both organisms, some studies that were carried out in mice don‟t 
translate into humans (26). There are well over 1000 mutant strains of mice and the 
majority replicates an inherited human genetic disease or a human disease phenotype. 
It‟s important to note that few models replicate all symptoms associated with complex 
human diseases. Diseases that are hard to replicate in mice, but may otherwise be 
studied in primates, include cognitive and neurodegenerative disorders (27). However, 
one of the greater successes of mouse models comes from studying tumorogenesis 
and the role of genes in promoting cancers. Neoplasia, abnormal proliferation of cells, is 
a hallmark biological process during the multistep development of neoplasm (tissue 
mass or cancer) (28). Mouse models have given us tremendous clues into identifying 
„Driver mutations‟, a genetic modification that provides an advantage to cells to facilitate 
tumor formation and survival (29). Gradually, the neoplasia accumulates more 
„passenger‟ mutations in other genes important for DNA repair, cell proliferation and 
death, angiogenesis and invasion, leading to neoplasm and metastasis. Mouse models 
have played a great role in understanding these processes and identifying critical gene 
mutations to drive tumorogenesis. Thus we will review some of the important models. 
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Breast cancer models. Breast cancer is one of the most diagnosed cancers in females 
and one of the primary sources of cancer-related deaths in the world. Mammary tissue 
in mammals undergo changes during pregnancy, lactation, and weaning of offspring, 
and therefore constantly undergoing angiogenesis, cell proliferation, and eventually 
senescence and apoptosis (30). Mammals share this phenomenon in all females, and 
studies on mice can ascertain the molecular mechanisms of the disease condition in a 
conserved manner. Transgenic mice that over-expressed the oncogene Myc in the 
mammary epithelium formed tumors in that region (31). The same group later reported 
on the synergistic roles of H-Ras and Myc in mammary tumors; these strains, in addition 
to others (ErbB2, TGFα) are still used to test drugs in mice that have breast cancer (30, 
32, 33). Later studies revealed that Brca1 (breast cancer 1, early onset) inactivation in 
mouse mammary tissue leads to genomic instability and tumor formation. This gene 
was then found to be mutated in a great percentage of women who have early onset 
breast cancer, and became a marker for breast cancer (34). Subdermal injection of 
foreign tissue, also known as Xenograft transplantation of tumors, is a mechanism to 
study tumor invasion and metastasis in mice, which lead to a better understanding of 
mutations that aide in angiogenesis, epithelial-mesenchymal transition, transplantation 
in other organs, and other features of breast cancer metastasis (30). Mouse models 
remain a useful tool for pharmaceutical companies and their active research to test new 
therapies for breast cancer.  
Colorectal cancer models. Colorectal cancer (CRC) is a heterogeneous disease that 
can be caused by accumulating somatic mutations due to aging, environmental and 
chemical exposure, or diet leading to sporadic CRC (35). CRC represents the third most 
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frequently diagnosed form of cancer. Familial adenomatous polyposis (FAP) and 
hereditary nonpolyposis colorectal cancer (HNPCC) are the most common types of 
hereditary CRC. Patients predisposed to FAP typically carry a germline mutation for the 
tumor suppressor gene adenomatous polyposis coli (APC) gene (36). Additionally, 
various somatic mutations of APC occur in about 85% of all sporadic CRC, and the 
majority of these mutations occur in the mutation cluster region (MCR) of the gene.  
Several mouse models that study early events of CRC have been developed and can 
be divided into three major pathways; the mismatch repair pathway, the non-Wnt 
pathway, and the Wnt pathway (37). The mismatch repair pathway was linked to 
HNPCC when mice deficient for DNA mismatch repair (MMR) proteins Mhl1, Msh2, and 
Msh6 developed gastric, intestinal, and colorectal cancers (38). The non-Wnt pathway 
mediated mouse models examine the role of transforming growth factor beta (TGF-β) in 
CRC and inflammation-mediated carcinogenesis (37). Studies on mice with TGF-β 
mutations showed a tumor suppressor role in early CRC and an enhancer of invasion 
and metastasis in late CRC. The Wnt pathway mutant mouse models provided a link 
between hereditary FAP and Apc mutations. The multiple intestinal neoplasia APC 
(ApcMin) mouse model was the first mouse model to recapitulate the human FAP 
disease and continues to be utilized as a model for synergistic activation of onco-genes 
in tumor progression (39). CRC mouse models can be use to study carcinogenic 
molecules and chemicals, chemotherapeutic agents, and the roles of everyday drugs 
like NSAIDs in CRC prevention and treatment.  
Models for other cancer hallmarks. There are other mouse models of human cancer 
which can‟t be categorized into a specific organ or class. However, there are many 
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models that describe other fundamental processes of cancer formation, progression, or 
invasion, and these models cover a wide spectrum of genes. Hanahan and Weinberg 
recently characterized the six biological hallmarks of cancer to be: „sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and metastasis‟ 
(28). Perhaps one gene above all else has been the centerfold of all cancer research, 
the tumor suppressor protein p53. Deregulation of p53 activity is seen in approximately 
70% of all cancers, and these are conserved estimates (40). Because of the complexity 
of the p53 pathway, its interacting proteins, and its direct-induced genes, it‟s likely that 
p53 contributes to all six fundamental hallmarks of cancer, hence the term‟ guardian 
angel of the genome‟. Several p53 mutant mouse models exist to study the extensive 
phenotypes caused by various mutations in p53. To mimic human mutations in p53 
which are typically single nucleotide polymorphisms (SNP), recent work has shifted 
towards recreating these SNPs in mouse models (41-43). These studies may contribute 
to the molecular mechanisms of increased tumor susceptibility of p53 polymorphisms. 
Future studies may also look into the effect of polymorphism of p53 effectors and 
response genes in tumor susceptibility and responsiveness to therapeutic agents. ATM, 
p21, and MDM2 are p53 pathway genes that have been reported to have polymorphism 
that contributes to cancer susceptibility, while polymorphisms in the promoters of p53 





Eukaryotic Transcription Regulation, and The Forkhead Box Family of Proteins 
Introduction to Eukaryotic Transcription Regulation  
Transcription is the fundamental process of the cell by which genetic information 
stored in DNA is activated through the synthesis of a complementary messenger RNA. 
Transcription is a highly regulated process in Eukaryotic cells at hierarchical levels that 
include pre-initiation, elongation, termination and epigenetic chromatin structure. 
Eukaryotic RNA Polymerase II, which is responsible for transcription of protein-coding 
genes, is composed of multiple subunits but lacks the capacity to initiate transcription in 
a purified form (44). Instead, the RNA polymerase requires the activity of general 
transcription factors to recognize a DNA sequence and initiate transcription of all genes; 
these „basal‟ transcription factors are TFIIB, D, E, F, and H (45). Schaffner and 
Chambon identified gene-specific „enhancer‟ elements that bind „activator proteins‟ to 
allow transcription of specific genes (46). Kornberg purified the „mediator‟ complex that 
links the regulatory elements of specific gene expression with general transcription 
factors and RNA polymerase. This introduced the concept of cis- and trans-regulatory 
elements that control the activation of specific-gene transcription. Transcription factors, 
known as trans-regulatory elements, can bind to specific sequences in upstream 
regulatory regions and gene promoters, known as cis-regulatory elements to selectively 
activate gene expression in a specific manner.  
Transcription Factors 
 Eukaryotic transcription regulation is mediated through transcription factors 
(trans-regulatory elements) that can act as either „Activators‟ or „Repressors‟ of 
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transcription. The primary domains of all transcription factors (TFs) include a DNA 
binding domain and trans-activation domain; however, many TFs include an additional 
ligand-binding domain (47). The majority of transcription factors possess DNA-binding 
domains that can recognize specific DNA sequences formed at the major grooves (48). 
DNA-binding domains can be generally broken down to one of five major classes: Basic 
domains (helix-loop-helix), helix-turn-helix (e.g. Homeodomains, winged/forkhead), Zinc 
finger domains, β-scaffold domains (e.g. MADs box), or steroid hormone receptor (49). 
These domains are amphipathic amino acids rich motifs with the DNA binding surface 
rich in aromatic amino acids. Transcription factors can homo- or hetero-dimerize and 
recruit the basal transcriptional machinery to initiate transcription; hetero-dimerization 
provides an additional layer of diversity in transcription regulation.  While the majority of 
transcription factors activate transcription, some function as repressor protein by binding 
to DNA sequences that overlap activator-binding sites or by binding to sequences that 
overlap a transcription start site.  
Transcription factors have a „Transactivation domain‟ (TAD) that links DNA 
recognition with recruitment of the transcriptional machinery. TADs are enriched with 
conserved acidic and hydrophobic amino-acids that are critical for transactivation of 
transcription (50). Some transcription factors have a nine-amino-acid transactivation 
domain, 9aa TAD (51). TAD is a common motif to a large number of yeast (Gcn5, Gal4, 
Oaf1, and Pho4) and animal transcription factors including VP16, p53, NF-IL6, NFAT1, 
and NF-κB. The TAD domain of these transcription factors interacts directly with the 
general transcriptional cofactor TAF9 (TAFII31), a component of TFIID and the basal 
transcriptional machinery. The third domain of most transcription factors is a ligand-
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binding domain or a sensory domain, which initiates transactivation of the TF, as in the 
case of Estrogen Receptor (ER) (52).  
Regulation of Transcription Factors 
Translation and nuclear localization 
 Activation of TFs is regulated at different levels in the cell to assure timely and 
tissue specific gene transcription. TFs, just like all functional genes, are transcribed in 
the nucleus and exported to the cytoplasm for translation into a functional protein. TFs 
are active in the nucleus and possess a nuclear localization signal (NLS), a sequence of 
positively charged amino acids exposed on the surface of the protein (53). NLS is then 
recognized by the Karyopherin family of proteins (include Importin and Transportin 
proteins) that transport the transcription factor through the nuclear pore into the nucleus 
in an ATP-dependent process (54). However, regulatory proteins can bind to 
transcription factors and sequester them in the cytoplasm by masking the NLS binding 
site, thus rendering the protein unable to translocate to the nucleus to activate 
transcription. Inhibitor of κB (IκB) binds and sequesters the transcription factor NF-κB in 
the cytoplasm, thus regulating it transcriptional activation function in a non-specific 
manner (55). Moreover, IκB achieves NF-κB sequestering in the cytoplasm by masking 
its NLS signal and preventing its translocation to the nucleus (56). Other TFs are 
sequestered by interactions with specific regulatory proteins. MDM2 is an E3 ubiquitin 
ligase protein and a negative regulator of the tumor suppressor TF p53; MDM2 binds to 
p53 in the cytoplasm and induces proteasome-mediated degradation of p53 (57). Beta-
catenin, a component of the Wnt signaling pathway, is another transcription factor that 
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is sequestered in the cytoplasm by binding to the transmembrane protein E-cadherin, or 
binding to APC/Axin/GSK-3β complex to mediate protesaomal degradation (58).  
Activation signals 
 Activation of TFs is a complex process that depends on the inherent domains of 
TFs (Ligand binding domain) and other regulatory proteins. In the case of steroid 
receptors (e.g. Estrogen, Glucocorticoids), binding of the steroid leads to dissociation of 
the cytoplasmic co-repressors (Src for ER, HSP70/90 for GR) and translocation to the 
nucleus, where the receptor dimerizes and binds to its response element and recruits 
additional co-activator proteins (59, 60). However, a more complex chain of regulatory 
proteins exists for the tumor suppressor protein p53. DNA damage triggers multiple 
kinases to phosphorylate p53 at Ser15 and Ser37 by ATM/ATR and DNA-PK (61). This   
phosphorylation weakens the affinity of MDM2 interactions with p53, thus promoting 
both the accumulation and activation of p53. Additionally, the checkpoint kinases Chk1 
and Chk2 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability and 
activity (62). This tetramerization of p53 occurs in the nucleus and masks the nuclear 
export signal (NES) to maintain p53 transactivation (63). Acetylation of p53 is a second 
modification mediated by p300 and CBP acetyltransferases, which enhances p53 DNA 
binding domain affinity to bind its response element (64). Another level of p53 regulation 
occurs through ARF, which binds to MDM2 and promotes its rapid degradation, thus 
stabilizing p53 and maintaining its transcriptional activity (65). In many instances, the 
transcription factor is found inside the nucleus, but is bound to a negative regulator. The 
Retinoblastoma protein (pRB) is a tumor suppressor protein that negatively regulates 
cell-cycle progression by binding to the E2F transcription factor and masking its 
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transactivation domain, thus inhibiting its transcriptional activation of genes that encode 
DNA replication proteins (CDC6, TK) (66). pRB is typically hypo-phosphorylated and 
bound to E2F; however, its interaction with E2F is reduced upon phosphorylation by 
checkpoint proteins Cyclin D/CDK4/6 and Cyclin E/ CDK2 to promote DNA replication.   
Transcriptional regulatory complexes 
 The TAD domain of TFs allows for competitive interactions with proteins or 
protein complexes that can either activate or repress transcription. These protein 
complexes recruit chromatin remodeling proteins that modify the DNA to allow for DNA-
binding domains of TFs to recognize their cis-regulatory sequences and promote gene-
specific transcription. TCF is a transcription factor that recognizes its cognate Lef-1 site 
on target genes; however, TCF is typically bound to Groucho, a protein that interacts 
with HDAC1 to repress transcription (67). Once the Wnt signaling pathway component 
β-catenin translocates to the nucleus, it displaces Groucho from TCF and interacts 
directly with TCF, allowing for gene transcription. The oncoprotein c-Myc is a 
transcription factor that binds E-boxes of DNA to activate transcription of specific target 
genes (68). C-Myc heterodimerizes with MAX, another transcription factor to enhance 
the specificity of DNA interaction of c-Myc. Upon binding to the E-Box, c-Myc interacts 
with histone acetyltransferase (HAT) enzymes to modify the chromatin and enhance 
transcription. However, Mad family of proteins compete for binding with Max and C-myc 
and can thus form heterodimers that can recognize the E-Box sequences (69). Mad-
containing dimers antagonize c-Myc dimers by interacting with the mSin3a protein, 
which in turn recruits histone deacetylase (HDAC) enzymes to compact chromatin and 
reduce transcription.     
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Transcription Factors and Signaling Pathways 
 Many transcription factors belong to conserved families of proteins that function 
in a signaling cascade to regulate gene expression. These signaling pathways are 
involved in multiple cellular and developmental processes and mutations to any 
component of these conserved pathways lead to an array of developmental disorders 
and cancers. Signaling pathways are used in multicellular organisms to communicate 
between cells and utilize ligands, growth factors, and receptors to initiate these 
changes. The mitogen-activated protein kinase/Erk (MAPK/Erk) signaling pathway is 
involved in cellular growth and differentiation, and is activated by a wide variety of 
receptors including the epidermal-growth factor receptor (EGFR) (70). EGFR is a cell-
surface receptor that belongs to the Erb family of tyrosine kinase receptors; it‟s 
activated by binding of the EGF ligand and the transforming growth factor α (TGFα) as 
they both function in cell proliferation and differentiation (71).   Activation of EGFR leads 
to sequential activation of an adaptor (GRB2), linking the receptor to a guanine 
nucleotide exchange factor (SOS) and transducing the signal to small GTP binding 
proteins (Ras), which in turn activates the core unit of the cascade composed of a 
MAPKKK (Raf), a MAPKK (MEK1/2), and MAPK (Erk). These proteins can then signal 
terminal transcription factors like Activating Protein 1 complex (c-Fos and c-Jun), c-Myc, 
and cAMP reponse element binding (CREB) to activate gene transcription (72).  
 The NF-κB transcription factor is an important regulator of cellular response to 
multiple stimuli, but most importantly those of cytokines and viral antigens, to mount an 
immune response and protect the organism (73). Amongst the transcriptional targets of 
NF-κB is the promoter of the kappa light chain, an essential component of antibodies 
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responsible for creating the diversity in the immune response. NF-κB activation is 
receptor mediated and involves different families including Receptor activator of nuclear 
factor kappa B (RNAK), a member of TNFR family, Toll-Like Receptors (TLR), and 
Interleukin Receptors (74). Ligand binding to these receptors activates one of two 
kinases, MEKK3 (MAPK/Erk Kinase Kinase 3) and NIK (NF-κB Inducing Kinase). Both 
kinases lead to activation of IKK to phosphorylate IκBα (Inhibitor of κB) and its 
degradation, thus exposing the NLS signal of NF-κB to translocate to the nucleus (75). 
Interleukin receptors can mediate another signaling pathway, the JAK/STAT pathway. 
Binding of Interleukins to their receptors leads to auto-phosphorylation of the JAK family 
adapter protein, which then proceeds to phosphorylate its target STAT family of proteins 
(76). This leads to dimerization of STAT proteins and translocation to the nucleus to 
activate transcription.  
 The Notch and Wnt signaling pathways are essential to eukaryotic embryonic 
development and tissue specificity. Notch is a transmembrane protein with an extra-
cellular and intra-cellular domain. There are four different Notch family receptors 
(Notch1-4) that can interact on the cell surface with five ligands (belong to Jagged and 
Delta families of receptors) (77). The Notch pathway regulates cell fate determination of 
neighboring cells through lateral inhibition, depending on their ability to express either 
the receptors or the ligands. Upon ligand binding to the extracellular domain of Notch 
receptors, two different proteases get activated: the ADAM proteinase family to cleave 
the extracellular domain, and the γ-secretase complex to cleave the intracellular 
domain. The intracellular domain then translocate to the nucleus where it interacts with 
multiple proteins to activate transcription (78). Similarly to the Notch pathway, the Wnt 
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signaling pathway is activated by binding of the Wnt ligand to the Frizzled receptor, 
which forms a complex with LRP and Dishevelled. Binding of the Wnt ligand activates 
the protein Dishevelled to bind to the “destruction complex” composed of Axin, APC, 
GSK-3β and Beta-catenin. Dishevelled then phosphorylates Axin thus weakening the 
affinity of the destruction complex and GSK-3β ability to phosphorylate β-catenin and 
target it for destruction (67). Β-catenin then enters the nucleus and activate transcription 
by binding to its Tcf/Lef1 sites.  
Superclass Helix-turn-Helix 
The Superclass Helix-Turn-Helix transcription factors share a unique DNA 
recognition domain. Family members of this Superclass include the Homeobox domain 
family (including Paired box), the Fork head / Winged helix family, the Heat Shock 
Factors, and the transcriptional enhancer factor (TEA) family (49). Perhaps the 
Homeotic box (HOX) family and the Forkhead Box (FOX)/Winged helix proteins family 
are the best known members of this superclass. The FOX family will be discussed in 
great details later in this chapter. Hox genes encode transcription factors defined by the 
DNA-binding domain termed the homeodomain that function independent of conserved 
signaling pathways (79). Hox genes are present in all animals and the homologues are 
highly conserved. Hox genes in vertebrates are located contiguously in clusters with the 
number of these clusters varying according to anatomic complexity. There are 4 Hox 
clusters in mammals (HOXA, B, C, and D) and 39 Hox genes have been identified in 
humans. Hox genes have been well studied in Drosophila, where they have been 
shown to be involved in normal temporo-spatial limb and organ development along the 
anterior-posterior (A-P) axis. There are three basic mechanisms utilized by Hox cluster 
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to regulate normal tissue development in vertebrates: spatial collinearity, posterior 
prevalence, and temporal collinearity (80). Spatial collinearity correlates the position of a 
Hox gene in the cluster with its tissue expression along the A-P axis. Normally, 3′ genes 
within the cluster are expressed in anterior tissues and 5′ genes in posterior tissues. 
Posterior prevalence postulates that Hox genes which are positioned more 5′ in the 
cluster will have a dominant phenotype to those more 3′. This is due to transcription of 
microRNA embedded along with HOX gene in the cluster; miRNA can then silence 
more upstream HOX genes. Temporal collinearity is similar to spatial collinearity but 
correlates temporal tissue order of expression of Hox gene with the cluster.  
 HOX proteins have been shown to effect essential cell processes like cell 
migration, cell cycle control, apoptosis, cell adhesion, and development. HOX proteins 
function at the „high level executive‟ stage during development, which denotes targeting 
of „executive genes‟ that encode transcription factors, cell-cell signaling, or morphogens 
(80). Decapentaplegic is an executive gene regulated by the Drosophila HOX gene 
Ultrabithorax and Abdominal-A, and it expression triggers cell shape changes in the gut 
that are required for normal visceral morphology. These two HOX proteins also regulate 
distal-less expression, a gene involved in limb formation. Meanwhile, Deformed is 
another HOX gene that regulates reaper expression, which in turn activates apoptosis 
during maintenance of the boundary of maxillary and mandibular segments of the head. 
HOX proteins are less well studied in higher mammalian development, but studies have 
shown a role in cell-cycle regulation and cancer. Hoxa10 appears to be activated during 
differentiation of mouse cultured myelomonocytic cells into monocytes followed by 
growth arrest; this was attributed to the induction of cell-cycle arrest protein p21 (81). 
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The Forkhead Box 
The forkhead family is a large family of transcription regulators that share a 
structurally related DNA binding domain: the forkhead (82, 83). Originally, the fork head 
gene (fkh) was discovered as a mutation in Drosophila melanogaster which presented 
with an ectopic/displaced head in larvae and a spiked head phenotype in adult flies. 
Expression of the fkh gene was determined to be in the terminal domains of the D. 
melanogaster embryo which correlate to the anterior head and posterior tail of an adult 
fly (84). Protein sequence analysis indicated the lack of a homeo domain in the fkh 
protein, and the sequence showed no similarity to any known protein family. The closest 
discovered homologous protein factor that had been identified to play a role in head/tail 
development was the spalt (sal) gene of the „region-specific homeotic genes‟ family 
(84). However, the fkh protein was not structurally related to the sal protein. Meanwhile, 
Lai and his group were able to clone the cDNA encoding Hepatocyte Nuclear Factor 3α 
(HNF3α) in rat liver (85). Sequence analysis of HNF3α revealed no similarity to the 
homeo domain protein HNF-1 or the Leucine-zipper protein C/EBP, which play a role as 
liver nuclear transcription factors. Lai and colleagues limited the DNA-binding region to 
amino acids 124-288 of the protein and predicted short α-helices based on the 
abundance of proline and glycine residues (85). Detlef Weigle and Herbert Jackle 
compared the Drosophila fkh protein with the mammalian HNF3α protein. In comparing 
the DNA-binding domains of both proteins, they noticed 86% identity and 92 % 
conservation in a 110 amino acids span of Drosophila and mammalian Fox proteins 
which contained the DNA binding motif (86). HNF3α was later renamed FOXA1 and the 
other HNF3β and HNF3γ proteins identified in the study were assigned to the FOXA 
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subfamily as FOXA2 and FOXA3 respectively. Subsequent crystallography of the 
FOXA1 protein revealed the structure of Forkhead proteins and its interaction domains.  
FOX crystal structure and phylogeny 
Clark et al first resolved the structure of HNF3γ (FOXA3) interacting with a 13 
nucleotide region of the transthyretin (TTR) promoter previously used to identify HNF3 
family of proteins. Crystal structure of the forkhead domain of FOXA3 shows the 
presence of three α-helices (H1, H2, and H3) at the N-terminus of the protein. There are 
also three β-strands (S1, S2, and S3) located towards the C-terminus of the FOXA3 
protein (87). A polypeptide sequence connects S2 and S3 to form the first loop (W1), 
and another polypeptide sequence is found after S3 to form the second loop (W2). S1 is 
found between helices 1 & 2 and interacts with S2 and S3 to form an anti-parallel B-
sheet. Different from homeo domains, The N-terminal region of Forkhead proteins 
interacts with C-terminal region via S1 to form a hydrophobic core. A closer look at the 
interaction of a FOXA3 monomer with TTR promoter shows interactions of H1 and H2‟s 
N-termini with the phosphate backbone of DNA likely in the minor grooves. H3 interacts 
with the major groove of DNA, and both wings border this interaction. The W1 and W2 
loops flanking the H3 interacting with the major grove yields a butterfly shaped 
interaction, which has given the term “winged helix” to Forkhead proteins. Side-chains 
of the helices and wings interact with DNA phosphate and ribose groups; this includes 
multiple W2 arginine residues found to interact with the minor and major grooves of 
DNA at specific nucleotide positions. Other residues were shown to interact specifically 
with sense or anti-sense nucleotides of the DNA fragment (87).  
26 
 
After the discovery and classification of the HNF3 proteins as the first members 
of forkhead/winged helix proteins, many scientists began to discover other proteins 
containing the same domain among various chordates (88). FOX (Forkhead Box) was 
adapted as the nomenclature for such proteins, and phylogenetic analysis further 
classified FOX proteins into 15 subclasses (FoxA through FoxS) depending on 
conservation of the forkhead domain. Arabic numerals designate members of a 
subclass of FOX proteins which depends on protein sequence (88). Homeobox genes 
(Hox) are a class of important transcription factors involved in development. 
Functionally related Hox, Parahox, and Nkx genes are clustered together in 
chromosomal regions (89, 90). However, no such clustering occurs for the Fox family of 
genes except for a few gene clusters. A cluster of FoxL1, FoxC, FoxF and FoxQ1 was 
identified in the chordate amphioxus. In humans, two different clusters were identified 
on chromosomes 16q24.3 and 6p25. On chromosome 16q24.3, the FOXL1, FOXC1 
and FOXF2 genes were found within a 70 kb span. At chromosome 6p25, the FOXC2, 
FOXF1 and FOXQ1 genes were found within a 325 kb span (90).  
FOX proteins and development 
FOX proteins differ from related Superclass helix-turn-helix HOX genes in their 
function as terminal transcriptional effectors rather than high-level executive proteins. 
FOX Proteins can function individually and redundantly as monomers or in an 
overlapping manner. FoxA1 and FoxA2 cooperate during endoderm differentiation into 
lung epithelium and during liver morphogenesis and hepatic specification (83, 91, 92). 
Moreover, FOXF1 and FOXF2 exhibit non-allelic and non-complementation functional 
overlap as homozygous Foxf2 mutants and Foxf1/Foxf2 heterozygotes displayed gut 
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and intestinal development problems including megacolon, colorectal muscle 
hypoplasia and agangliosis (91). Mutations in FOXO3a and FOXL2 result in premature 
ovarian failure (93). Foxc1 and Foxc2 have interactive and essential roles in cardiac 
morphogenesis because compound heterozygotes exhibit similar cardiac or renal 
phenotypes to single null mutants (94). Foxd1 and Foxd2 also exhibit an additive and 
synergistic role in renal development, and Foxc1 and Foxc2 also appear to affect renal 
development especially migration of renal cells (95). Foxc1, Foxc2, and Foxl2 are 
expressed in the neural-tube derived ocular tissue and mutations in these genes lead to 
abnormalities in ocular development. Many FOX genes (Foxd3, Foxc1, Foxc2, Foxl2) 
are expressed in the neural crest and mutations to these genes result in cell-migration 
defects and organ defectsFoxb1b deletion results in neural tube closure defects, 
reduced posterior body axis and embryonic lethality, while Foxh1 mutations affects left-
right axis specifications (95). FOXE1 is involved in cranio-pharyngeal development and 
mutations lead to thyroid agenesis and other phenotypes. Foxi1 is responsible for inner-
ear development, especially the vestibulum and cochlea (96). Foxn1 and Foxp3 
mutations exhibit severe immune-system defects, as Foxn1 is highly expressed in skin 
and thymus tissue and maintains balance between proliferation and differentiation (95).  
FOX proteins and transcription 
Forkhead box proteins can bind DNA as monomers and independently regulate 
transcription by working as activators, repressors, or can have a dual function. FOXD2 
over expression was shown to bind the RIα1b promoter and increase its sensitivity to 
cAMP, thus inducing RIα mRNA and protein level, which is involved in T-cell activation 
(97). Additionally, the FoxD2 avian homologue (CWH-2) was shown to act as 
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transcriptional repressor by binding to Qin/BF-1 promoter sites of genes involved in 
brain development and oncogenesis (98). In some cases, splice variants of the same 
gene can function as activators or repressors (99). The Foxm1 (Human homologue 
TRIDENT/FKHL16) protein is a winged helix protein specifically expressed in rapidly 
dividing cells and is involved in controlling mitosis and promoting S phase and G2/M 
phase progression (99, 100). The 396BP region upstream of the Foxm1 gene start 
codon is responsible for modulating and transducing growth factor stimuli to effect 
expression of Foxm1 (100). FOXM1a is a splice variant of the FOXM1 gene which binds 
the FOXM1 consensus sequence but does not trans-activate genes. However, FOXM1b 
and FOXM1c are involved in the activation of many genes (c-myc, c-fos, Cyclin-B, 
Cdc25B) involved in cell-cycle regulation, genomic stability, and tumorogenesis (99).  
Additional diversity in FOX proteins regulation of transcription can be achieved by 
interacting with signal transduction protein complexes. The forkhead activin signal 
transducer-1 (FAST-1) or FOXH1 is a forkhead protein that interacts with human Smad2 
and Smad4 to activate the Activin Response Element (ARE) (101). The activation of the 
ARE by the complex is dependent on the presence of a TGF-β stimulating peptide, 
which suggests the FOXH1-Smad complex functions as a signal transduction cascade 
in the TGF-β pathway. Seoane, et al presented more evidence supporting a role for 
FOX proteins in signal transduction when they showed a role for FOXO family of 
proteins in regulating p21Cip1 through a TGF-β signaling pathway. FOXO proteins were 
shown to form a complex with Smad2, 3, and 4 and positively activate p21Cip1 and relief 
its c-myc repression (102). Moreover, FOXG1 was shown to be a negative regulator of 
the Smad-FOXO induction of p21Cip1 in neuroepithelial cells by interacting with Smad-
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FOXO complex. FOXG1‟s role in progenitor neuro-epithelial cell development was 
previously studied, and it was shown to be a transcriptional repressor to differentiation 
signal stimulation (103). Foxg1 plays a similar role in the regulation of Foxh1 during lung 
development. Analysis of glioblastoma multiforme tumor samples and cell lines showed 
an increased expression of FOXG1, which suggests a role for the silencing of TGF-β 
mediated p21Cip1 induction (102). Other FOX transcription factors function as terminal 
effectors for other conserved signaling pathways including Hedgehog, Insulin/IGF, Wnt 
signaling pathway, and MAPK/Erk (93).  
FOXN Subfamily 
The N subfamily of FOX proteins was first discovered when Li and colleagues 
identified the human T-cell leukemia virus enhancing factor (HTLF) as protein that 
bound the human T-cell leukemia virus long terminal repeat (HTLV-1 LTR) at the -117 
to -155 region (104). The DNA binding domain of the HTLF resembled the forkhead 
protein which was newly characterized, and the HTLF was later identified as the second 
member of the N-Subfamily (FOXN2). The FOXN subfamily received more significance 
when Nehls and colleagues were able to clone the nude locus of mouse chromosome 
11 (105). Characterization of the protein encoded by this region yielded a 648 amino 
acid protein with a DNA binding domain that resembled the forkhead domain (105). 
Interestingly, the newly discovered protein showed a 56% identity to the human T-cell 
leukemia virus enhancing factor (HTLF), which was earlier identified by Li and 
colleagues. The protein, later assigned FOXN1, was found to be mutated in nude mice 
which have rudimentary thymus and lack a T-cell induced immune defense (106). 
Down-regulation of hair keratins, abnormal morphogenesis of hair follicles, and failure to 
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develop a thymus from the ectoderm are characteristics of nude mice (106). FOXN1 
expression was later shown to be regulated by Wnt4 of the Wnt pathway which utilizes 
the PI3K-Akt to phosphorylate FOXN1 in thymic epithelial cells (107). Pati and 
colleagues isolated a high-copy suppressor of the S. cerevisiae MEC1 G2-M checkpoint 
mutants that conferred increased survival of G2-M checkpoint mutants (108). The 
protein encoded by the cDNA was called Checkpoint suppressor 1, and characterization 
of the full length protein showed homology to the forkhead/winged helix DNA binding 
proteins (108). Moreover, CHES1 sequence showed high homology to the human T-cell 
leukemia virus enhancing factor (HTLF) with 51% identity and 69% conserved residues. 
Identification of members of the N subfamily continued when Gouge and colleagues 
used the forkhead domain of Foxg1 to screen a mouse‟ eye cDNA for new proteins 
utilizing low-stringency hybridization (109). They identified FoxN4, a 523 amino acid 
polypeptide where sequence analysis predicted an activation domain and a DNA 
binding domain. The later domain showed high similarity to HTLF/FOXN1, and in-situ 
hybridization analysis showed specific expression in neural tissue and exclusively in the 
retina after embryonic day E13.5 (109). Most recently, Katoh was able to clone and 
identify FOXN5 and FOXN6 who share a 69 amino acid FN56 domain in addition to the 
forkhead domain (110, 111). In a study on FoxN expression in Xenopous laevis, FoxN5 
mRNA was shown to be maternally expressed, and FoxN5 transcripts are degraded 
during gastrulation and completely eliminated by neurlation (stage 15) (112). 
Interestingly, FOXN6 mRNA was shown to be expressed in breast cancer cell lines and 
primary breast cancers, and FOXN5 was associated with the human B-cell 
CLL/lymphoma 9-like (BCL9L) gene. A nuclear complex, which consists of BCL9L, 
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human T-cell leukemia virus enhancing factor, and beta-catenin, is shown to activate 
Wnt signaling pathway dependent expression of many genes including the oncogene 
Myc (113). 
FOXN3 (Checkpoint Suppressor 1) 
FOXN3 (also known as Checkpoint suppressor 1, FoxN3) belongs to the N 
subfamily of forkhead box transcription factors. Initial discovery and characterization of 
the protein was done by Pati and colleagues when they screened checkpoint-mutant 
Saccharomyces cerevisiae transfected with human cDNA for rescue of phenotype 
(108). Tx23, a human cDNA isolated from U118 glioblastoma cell line, was isolated as a 
high-copy suppressor of the S. cerevisiae MEC1 G2-M checkpoint mutants. The protein 
expressed by the tx23 cDNA, Checkpoint Suppressor 1 (CHES1), conferred increased 
survival of mec1-1 mutants to methyl methanesulfonate (MMS), UV radiation, and 
ionizing radiation which are DNA damage agents. Meanwhile, full length cDNA of the 
CHES1 protein restored G2-M checkpoint function in rad9 and rad24 mutants to 
wildtype levels. Analysis of the CHES1 protein encoded by the full length cDNA showed 
a novel protein that shares a common region with the forkhead/winged-helix family. The 
protein showed greatest homology to the human T-cell leukemia virus enhancing factor 
(HTLF). Interestingly, the 200 amino acids at the carboxy terminus of the CHES1 
protein isolated were sufficient to restore the mec1-1 G2 checkpoint mutants in S. 
cerevisiae (108). However, the carboxy terminal did not encode for the forkhead DNA 
binding region.  
32 
 
The C-terminal portion of the human FOXN3 protein was found to interact with 
Sin3, a component of the Sin3/Rpd3 histone deacetylase complex (HDAC) in budding 
yeast (114). The Sin3/Rpd3 HDAC complex is targeted to specific promoter regions via 
Sin3 interactions with site-specific DNA-binding proteins (115). CHES1/FOXN3 appears 
to inhibit the activity of Sin3/Rpd3 as deletion of Sin3 in Rad9 deficient S. cerevisiae 
conferred resistance to UV damage similar to the results seen upon CHES1 introduction 
to Rad9 deficient S. cerevisiae (114). Other studies showed the C-terminus of FOXN3 
represses transcription when targeted to a reporter promoter in cell lines derived from 
tumor tissues, which is consistent with its interaction with the Sin3/Rpd3-HDAC complex 
(116). Moreover, CHES1 interacts with the C-terminus region of the Ski-interacting 
protein, SKIP; this interaction varies from the well conserved SNW protein-binding 
domain of SKIP (116). SKIP is a well-conserved nuclear regulatory protein involved in 
pre-initiation of transcription, splicing and polyadenylation of RNA (116, 117). In addition 
to the Ski protein, SNW/SKIP interacts with many proteins including the tumor 
suppressor protein Retinoblastoma and receptor-regulated Smad2 & Smad3 proteins, 
which are TGF-β modulators (117). SKIP functions to recruit either activation or 
repression complexes to mediate multiple signaling pathways that are involved in cell 
proliferation and differentiation (118). CHES1‟s transcriptional repression of the GAL4 
reporter promoter can be correlated to CHES1‟s interaction with SKIP, which has been 
shown to recruit many repression complexes, including mSin3a, HDAC1, HDAC2, and 
NcoR/SMRT (116, 119). Case reports on human patients with deletions of the 
chromosomal region containing FOXN3 have shown phenotypes that include, 
dysmorphic features, delayed development, absent speech, auditory neuropathy, 
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craniofacial defects, dental anomalies, microcephaly (abnormally small head), skeletal 
defects, and hypotonia (120, 121).  
The human FOXN3/CHES1 has been mapped to 14q32.11 while the mouse 
Foxn3 was mapped to chromosome 12, region E (108). The human FOXN3 gene 
encodes a 490 amino acids protein with a predicted molecular weight of 54 kDa, while 
the mouse Foxn3 encodes a 457 amino acids protein with a predicted molecular weight 
of 50 kDa. Human FOXN3 has a splicing variant which is encoded by exon VI and adds 
an additional 66 bp (22 amino acids) to the gene transcript. Also, There is a variable 
leader exon which is used equally in both splice variants (112). In-situ hybridization 
analysis using FoxN3 probes in Xenopus laevis shows a persisitent expression in the 
eye, the branchial arches and the vagal ganglion.  
  The role of FoxN3 in mammalian development is not known due to the lack of 
data relating to animal models that are defective in FoxN3 expression. However, recent 
studies have shown the involvement of FoxN3 in craniofacial and eye development in 
Xenopus laevis (122). X. laevis larvae injected with FoxN3 antisense morpho-olino (MO) 
were shown to have reduced eye size, reduction and false positioning of craniofacial 
cartilages, increased apoptosis in the brain, and reduced food intake. Cranial nerves, 
including hypoglossal and branches of the trigeminal nerve, were either lost or severely 
deformed especially nerve branches that innervate the lower jaw. The severity of the 
phenotype progressed with the developmental stage of the X. laevis larvae beginning at 
stage 41 onward and ending at stage 50 when reduced food intake ultimately lead to 
death. The severity of phenotype was also antisense MO dose dependent with greater 
and a more severe phenotype being produced with complete reduction of FoxN3 (122). 
34 
 
This may suggest that nullyzygoisty for FoxN3 in higher mammals would be lethal while 
heterozygosity may demonstrate phenotype.  
Foxn3 mouse model 
In an effort to understand the role FoxN3 in mammalian development, we have 
developed a mutant mouse model for the Foxn3 gene. Foxn3 deficient mice were 
generated using the Baygenomics gene trap embryonic stem cell resource. The 
Baygenomics insertional mutagenesis strategy involves the use of a gene-trap cassette 
consisting of a splice-acceptor-βgeo cassette (β-galactosidase-neomycin fusion gene) 
and characterized using 5‟ RACE (Figure 1). We obtained one of the ES cell clones that 
had been characterized to have a gene trap insertion within the Foxn3 gene for analysis 
of the gene trap insertion site. Using multiple intronic forward primers and a gene-trap 
specific reverse primer for PCR amplifications and sequencing, we determined the 
gene-trap insertion site to be in intron 3 (Figure 2). Foxn3-targeted ES cells were used 
for blastocyst injections using the microinjection services at the University of 
Massachusetts Medical School, Worcester.  Germ line founder mice were generated 
and the colonies were expanded for the analysis of the mutant offspring. The working 
model for the Baygenomics gene traps encompasses the splicing of the 5‟ splice site of 
Foxn3‟s exon 3 (encoding the first 218 amino acids) into the 3‟ splice site in the gene 
trap (123). This allows for the in-frame fusion of the first three exons of Foxn3 to the B-
galacotsidase neomycin sequence and the expression of this fusion protein. The 
expression of this fusion protein is mandated for the blastocysts to survive neomycin 
selection. Upon efficient splicing of the Foxn3 gene into the gene trap, the remainder 
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exons will not be translated and thus the wild type protein will be haplo-insufficient in 
heterozygous progeny and completely lost in nullisomic progeny. 
 
Figure 1. Schematic representation of the Baygenomics gene trap integrated into intron 3 of Foxn3 gene. 
The gene trap cassette contains an Engrailed 2 intronic sequence followed by a splice acceptor 
site, an ATG-less B-galactosidase neomycin fusion gene and a ploy-A site. 
 
 
Figure 2. Schematic representation of the strategy utilized to configure the gene-trap insertion site in 
intron 3 of the Foxn3 gene. Foxn3 Intron 3 forward primers were designed at 2kB space intervals 
and tested against one gene-trap specific reverse primer in WT and Heterozygous mice. 
Sequencing of the PCR product indicated that the gene trap was integrated within intron 3 (15,450 








En2: Engrailed 2 intron sequence          SA: Splice Acceptor site 
β-Geo: β-gal-neomycin fusion gene SV40pA: SV40 poly A 
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Materials and Methods 
Polymerase Chain Reaction (PCR) 
A nested PCR strategy was used to genotype the tail DNA of mice. Initial genotyping of 
tail DNA was done by southern blot analysis, which is time consuming and 
cumbersome. Gene-trap specific primers spanning 350nt (gene-trap relative positions: 
1665 forward primer and 2000 reverse primer) were initially used to distinguish between 
wildtype and mutant progeny. Intronic primer 3.33X was used as a forward primer and 
984r was used as a gene-trap reverse primer to authenticate the insert site in the 
mutant progeny. To distinguish heterozygous from nullisomic progeny, Intronic forward 
primer 3.33x and intronic reverse primer 400 reverse (position relative to 400nt after 
gene trap end site) were used. The PCR reaction mixture consisted of 10X PCR buffer 
(50 mM KCl; 10 mM Tris-HCl final concentration), MgCl2 (3mM final concentration), 
dNTP (200μM final concentration of each), forward and reverse primers (0.4 μM final 
concentration), Platinum Taq (0.5U final concentration), and ddH20 to a final reaction 
volume of 25 μl. The PCR conditions were as follows: an initial denaturation step of 5 
minutes at 94°C, followed by another denaturation step of 30 seconds, annealing for 30 
seconds at 58°C, and extension for 90 seconds at 72°C. This was repeated for a total of 
32 cycles. A final cycle of 72°C for 5 minutes was also included. The PCR products 
were run on a 1.5% agarose gel at 95 V for approximately 1 hour. Ethidium bromide 
was used to visualize the bands, and the gel was photographed using the Epichem3 
Darkroom and analyzed using LabWorks GelPro Application. The presence of a 350BP 
band with the gene-trap specific primers or the presence of a 1.5KB band in the insert 
primers indicated at least one gene trapped allele and thus heterozygousity. The lack of 
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a band in the two intronic primers indicated a nullisomic progeny, while the presence of 
a 1.2KB band indicated a heterozygous progeny.  
PRIMERS 
Primers used genotype analysis  
GS1 (Forward): TGATGCTCTCTCTACCAGTGGGAT  
GS2 (Reverse):  ATACACAGCACCCACTCCTATCCA  
TR1 (Reverse):  CCCAACTGACCTTGGGCAAGAACATA  
 


























Micro Computed Tomography (mCT) Image analysis 
High-resolution CT images were acquired using a MicroCAT™ II + SPECT instrument 
(Siemens Medical Solutions, Molecular Imaging, Knoxville, TN).  Each image comprised 
360 projections at 1 degree intervals and was acquired with X-ray source energy of 80 
kVp.  CT data were rendered using the Amira 3-D image analysis software package 
(Amira, Version 3.1: Mercury Computer Systems, Chelmsford, MA). Foxn3 deficient 
mice were isolated at 9.5, 11.5, 13.5, 18.5 day post coitum and 8,40 day old mice from 
various matings. Cranium was isolated and placed in Bouin‟s fixative or 10% formalin. 
Micro CT analysis were performed by Dr. Jon Wal at the University of Tennessee‟s 
Medical Center. 
RNA isolation and RT-PCR protocol 
Total RNA was extracted using Trizol according to the manufacturer‟s instructions 
(Invitrogen) from MEFS and various tissues from adult mice (3 months of age).  For 
expression analysis of skulls, the brain tissue was removed from neonatal mice and the 
remainder of the tissues was homogenized.  First strand cDNA synthesis was 
performed with 2µg of total RNA (pretreated with RNAse free DNAse) with random 
hexamers and M-MLV reverse transcriptase (Promega) for 1 hour at 42oC followed by 
inactivation of the reverse transcriptase at 700C for 15 minutes. A similar amount (2µg) 
of total RNA (pre-treated with RNAse free DNAse) was subjected to the above 
mentioned conditions in the absence of M-MLV reverse transcriptase. For PCR assays, 
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2µl of the reaction mixture (from a total of 40 µl) obtained from the first strand cDNA 
synthesis reaction was used. The PCR conditions were 940C for 2 min, followed by 30 
cycles at 940C for 30 sec, 580C for 30 sec and 720C for 10 sec.  PCR products were 
resolved by agarose gel electrophoresis and stained with ethidium bromide. 
Expression analysis of Foxn3 during mouse development 
Embryos obtained from timed matings from wild-type females and Foxn3+/H males were 
fixed with 2% paraformaldehyde and stained in a solution containing X-gal (2 mM 
MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40, 5 mM potassium ferricyanide,  5mM 
potassium ferrocyanide, 0.1 M phosphate buffer, pH 7.3).  Genotypes of embryos were 




The results of this chapter were published in a manuscript titled “Foxn3 is essential for 
craniofacial development in mice and a putative candidate involved in human congenital 
craniofacial defects” (124).  
Published results. 
Genomic DNA isolated from ES cells were analyzed by PCR to confirm Foxn3 
disruption by using primers (spanning 2 kb intervals) that were specific for Foxn3 intron 
3 and the gene-trap sequences. After obtaining one specific band in heterozygous DNA, 
we confirmed the authenticity of the band by obtaining other forward primers in the 
region and running PCR analysis to confirm the band size. Similar analysis was done 
utilizing other reverse primers from the gene-trap (Figure 3). Sequencing of the PCR 
product indicated that the gene trap was integrated within intron 3 (15,450 bases from 





Figure 3. PCR analysis of multiple forward primers of intron 3 of the Foxn3 gene. Left figure shows the 
banding pattern obtained from running one gene-trap specific reverse primer with multiple 
forward primers in WT and heterozygous mice. Right figure shows the isolated forward primers 
with variable gene-trap specific reverse primers.   
 
After confirming the insertion site of the gene trap, we designed an intronic 
reverse primer 400 BP after the insertion site. This reverse primer was designed to yield 
a 1.2KB band when run with a specific intronic forward primer. This product can only be 
made in the heterozygous mice because they still maintain a wildtype copy of the 
FoxN3 gene (Figure 4). The insertion of the gene trap extends this 1.2Kb product to 
approximately 10KB in the mutant chromosome, which is not amplified by a PCR 
analysis. Therefore, our nullizygous mice will not show a product for this specific PCR. 
This allows us to differentiate heterozygous versus nullizygous mice without utilizing a 
southern blot.  
3.11 3.12 3.13 3.14 3.15 3.17 3.18 3.19 3.16 
+ 984r 




















Figure 4. Schematic representation of the Foxn3 chromosome locus in wild type, heterozygous, and 
nullisomic mice. A. schematic representation of forward and reverse primer pair (GS1 and GS2) 
used for genotyping of Foxn3 mutant mice. B. Wildtype allele of Foxn3 intron 3 showing relative 
positions of the primer pair and the gene trap. C. Mutant allele showing the Insert PCR primer pair 
(GS1 and TR1) used for identifying Foxn3 mutant mice. D. Agarose gel electrophorysis analysis of 
wildtype, heterozygous and nullisomic Foxn3 mice and the primer pair used for each genotype. 
At the protein level, the insertion of the gene trap was determined to be within the 
C-terminal portion of the Fork-head box domain and upstream of three C-terminal exons 
encoding the SIN3 binding domain. The truncated FoxN3 protein yields a FoxN3-βgeo 
fusion protein containing the first 218 amino acids of the 457 amino acids protein 
b. WT allele 





























(Figure 5). Once we were able to genotype the mouse colony and the offspring of 
matings, we analyzed the embryonic and post-natal lethality of FoxN3 mutant mice. 
Analysis of Heterozygous matings at neonatal day 1 shows 61% survival of the 
Nullisomic offspring which indicates some embryonic lethality (Table 1). Further analysis 
of these offspring during weaning (day 21) shows a 25% survival of the null offspring, 
which further confirms the lethality of the FoxN3 mutant mice.  
 
 
Figure 5. Schematic configuration of the FoxN3 gene. A. Schematic representation of the FoxN3 gene 
showing its exons, introns, and gene-trap insertion site. B. NCBI analysis of the insertion site at 
the FoxN3 protein. Notice the loss of the C-terminal SIN3 binding domain as well as a portion of 
the Forkhead box. C.Schematic representation of the fusion protein containing the first 218 amino 










































Table 1. Embryonic and postnatal lethality of FoxN3 mutant mice.  Neonatal pups and offspring at 
weaning were genotyped for FoxN3 disruption using PCR. The total number of intercrosses (n) 
analyzed for each group and the expected numbers of mice based on Mendelian ratio are 
indicated within parentheses. 
Developmental 
stage 






71     21        38(42)     13(21)       61% 
Weanlings at 
day 21 (n=7) 
55     16        35(32)       4(16)       25% 
 
We analyzed Foxn3 expression patterns in embryos obtained from timed matings 
between wild type and Foxn3 heterozygotes.  Foxn3 expression was limited to the 
craniofacial regions and the developing vertebral column during embryogenesis (Figure 
6).  Importantly, Foxn3-β-gal expression was specific only to the heterozygotes (as 
determined via the genotyping of the yolk sacs) and the wild type embryos did not show 
any staining for β-galactosidase.  Analysis of Foxn3 gene expression in tissues from 
adult mice indicated a differential expression pattern with the highest expression in the 




Figure 6. Expression analysis of Foxn3 during embryogenesis.  Embryos obtained from wild type and 
heterozygote intercrosses at E11.5 and E13.5 were fixed in 2% paraformaldehyde, stained with X-
gal overnight and photographed. Representative photographs show Foxn3 heterozygous embryos 
(stained blue in panel b b, panel c (bottom), panel f and panel g and control wild type littermate 
embryo Panel a, panel c (top) and panel e that were stained similarly. Panel h shows RT-PCR 
expression of Foxn3 in various adult tissues.  
 
Examination of the developing mice showed that homozygous mutants exhibited 
severe runting and reduction in head circumference, which is indicative of craniofacial 
developmental defects (Figure 7). The average body weights of the wild type and mutant 
animals at weaning were 13.5 +0.70g (FoxN3+/+, n=3), 12.9+ 0.70g (FoxN3+/m, n=6), 




Figure 7. Photographs of FoxN3 WT and mutant mice at P8 and P11 showing the runting phenotype.  
To further characterize the microcephaly phenotypes, we performed imaging 
studies of the mutant and wild type littermate controls at stages P2, P8, P10, and P11 
using micro-computed tomography. A majority of the homozygous mutants and a minor 
subset of heterozygotes showed cranial vault defects of the skull, delayed suture 
closure and defects in the frontal, parietal and occipital bones of the skull (Figure 8 b-d).  
Subsequent histological analysis of calvariae obtained from 11 day old WT and 
homozygous mutant littermates indicated a drastic reduction in calvarial bone formation 
in the mutants (Figure 8 d) that was consistent with the mCT-scans that showed a 
reduced density in the homozygous mutants [compare Figure 8 c (bottom panel) and 
Figure 8 d].  Examination of the mandible showed reduced size and midline fusion that 
prevented further growth (Figure 8 e). There were apparent midline defects indicative of 
defective development of the basispehenoid, basioccipital, tympanic, and palatal bones 








Figure 8. Craniofacial skeletal developmental defects in Ches1 mutants. A-B: Isosurface rendering of 
micro-computed tomography (CT) images of the skull images of  8 day old WT and mutant pups 
are shown in panels A (lateral  view) and B (coronal plane of the dorsal aspect).  The mutants have 
reduced bone structure in the skull bones that appear as hollow structures because image thresh-
holding was optimized for viewing the calcified structures.  C: Coronal planar view through base 
of skull.  D: CT scan comparison of 11 day old wt and homozygous mutant pups.  E: Volume 
texture rendering of microCT images of 2 day old wild type and mutant littermate pups shows 
retarded growth of the mandible which appears to be fused at the midline prematurely.  For 
comparison, the premaxillary area (1), basispehenoid (2), basioccipital (3), and tympanic bones (4) 
are indicated in the WT animal on the left.  High-resolution CT images were acquired using a 
MicroCAT™ II + SPECT instrument (Siemens Medical Solutions, Molecular Imaging, Knoxville, 
TN).  Each image comprised 360  projections at 1 degree intervals and were acquired with an x-ray 
source energy of 80 kVp.  CT data were rendered using the Amira 3-D image analysis software 





We also performed histological analysis of the calvaria in 11 day old wildtype and 
null mutants which show a reduction in the thickness of the calvaria in the mutant 
animals (Figure 9).  
  
 
Figure 9. Histological assessment of calvaria in 11 day old wild type (left) and homozygous mutant (right) 
littermates.   Notice the calvaria is reduced in thickness in the mutant mouse.  Saggital sections of 
the skull were made stained by hematoxylin and eosin and photographed at the same 
magnification (20X).  Identical areas of the same width and length beginning from the connective 
tissue of the scalp are shown.  The drastic reduction in the skull bone thickness of the mutant 
allows for visualization of a portion of brain in the mutants whereas the same are in the wild type 




Furthermore, a subset of mutant animals exhibited eye migration defects. When 
we compared 13.5 d.p.c wildtype and null mutant embryos, we noticed a cranium 
development problem, microencephaly, and eye migration problems and size reduction 
(Figure 10).   
 
 
Figure 10.  Compound microscope images of 13.5 and 14.5 d.p.c. wildtype and null embryos. In the left 
figure, FoxN3 null embryo exhibits microencephaly phenotype along with eye size reduction and 
migration defect. In the right figure, FoxN3 null embryos show a great reduction in eye size that 
could be linked to an eye migration defect.   
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In addition to the craniofacial defects, among the small fraction of the surviving 
homozygous mutants and the heterozygotes, a high percentage of the mutant mice also 
presented malocclusion due to elongated incisors. Examination of 5 month old adult 
mutant mice indicated an overall growth retardation of the mutants and scoliosis like 
phenotype (hunch-back spine) in comparison to WT littermates. To correlate the 
phenotypes of the FoxN3 mutant mice, we performed a comparative analysis of human 
patients with congenital disorders and deletions of the human FoxN3 chromosomal 
locus (14q32.11) reported in the literature.  Interestingly, there was a substantial overlap 
of the clinical features of human patients and the FoxN3 mutant mouse model further 
underlining the importance of FoxN3 in craniofacial development (Table 2. Phenotype 
comparison of human patients with 14q deletions and FoxN3 mutant mice.). 
Table 2. Phenotype comparison of human patients with 14q deletions and FoxN3 mutant mice.  




Growth Retardation + + 
Microcephaly + + 
Eye deviations + +/- 
Eye lid opening defects + +/- 
Dental abnormalities + + 
Ear abnormalities + ND 
Scoliosis + + 
Jaw abnormalities + + 






To examine the mechanism by which FoxN3 affects craniofacial development, 
we tested the expression of several genes known to regulate bone morphogenesis. 
Total RNA was extracted from cranium of P0 wildtype and homozygous mutant mice 
and cDNA was synthesized. FoxN3 levels were reduced in FoxN3 null mice compared 
to wildtype; however, there was leaky expression of the wildtype mRNA (Figure 11). 
This leaky expression could be beneficial as the FoxN3 gene may act as a hypomorphic 
allele, and the complete knockout of FoxN3 may cause the death of homozygous 
mutant mice during embryogenesis. Additionally, FoxN3 homozygous mutants showed 
reduced expression of the Bone morphogenetic proteins 2 and 4 (Bmp2 and Bmp4) 
compared to the wildtype littermates (Figure 11). Similar expression patterns were 




Figure 11. Reduced expression of osteogenic genes in Foxn3 mutant mice and cell lines. Total RNA 
was isolated from neonatal (P1) skulls (a) and MEFs (b) of wild type and homozygous mutants.  
RT-PCR analysis was performed with primers specific for the indicated genes and the house-




Role of Foxn3 in Mammalian Development 
The culmination of our data indicate that the Foxn3 gene plays a crucial role in 
mouse development as the hypomorphic mutant mice displayed craniofacial 
developmental defects that lead to embryonic and postnatal lethality.  The craniofacial 
developmental defects in the Foxn3 mutants are also correlated with the craniofacial 
tissue specific expression of Foxn3 during embryonic development.  Furthermore, the 
phenotypes of the Foxn3 mutant mice are consistent with recent studies that have 
shown the involvement of Foxn3 in craniofacial and eye development in X. laevis (122). 
More importantly, the comparative analysis of the phenotypes of the Foxn3 mutant 
mouse model with the clinical features of human patients with deletion of the FOXN3 
locus shows a substantial overlap of the phenotypes that provide initial clues to the role 
of FOXN3 in craniofacial development and underline its importance in mammalian 
development (Table 2). 
The mouse model we have described was generated utilizing the gene-trap 
strategy and involves the random disruption of genes in mouse embryonic stem cells. 
There are many advantages and disadvantages to choosing the gene-trap approach 
over the conventional knockout strategy. The gene-trap is a cost efficient, high 
throughput technology that allows the phenotypic screening of many genes in a short 
amount of time (125). The Engrailed-2 intronic sequence simulates the intronic region 
present in a mouse intron, which allows for the spliceosome machinery to bind and 
recognize the sequence. The splice acceptor (SA) site adds the last exon in-frame to an 
ATG-less B-galacotsidase-neomycin gene followed by a stop codon and a ploy 
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adenylated tail. Upon efficient splicing of the gene into the gene trap, exons upstream of 
the gene-trap will be fused in-frame to the B-galacotsidase neomycin gene and express 
a fusion protein while the remainder exons will not be translated. Nevertheless, this 
fusion protein can cause a dominant-negative phenotype as reported by our group or 
may result in the loss of cytoplasm-nuclear shuffling (126). Although gene-trap based 
mutations can give rise to the dominant-negative phenotype, a classical homologous 
recombination based germ-line knockout can give rise to a similar phenotype as was 
the case in Terry Van Dyke‟s attempt to remove exons 2 and 3 from the Bub1 gene 
(127). However, an inefficient splicing of the upstream exon in to the downstream exon 
(via the circumvention of the splice acceptor present in the gene-trap) has been shown 
to occur in a minor percentage of gene trap mutants by our group and others (126, 128). 
Yet, this leakiness in the gene-trap allows for examining the functions of genes which 
will be lethal in null progeny (e.g. Bub1) (129). Another advantage for using the gene-
trap is the tissue-specific reverseal of the gene trap by the expression of a Cre 
recombinase that clips two LoxP sites flanking the SA site. The Cre recombinase is 
driven by the binding of a tissue-specific protein to activate the Cre-gene promoter.  
Interestingly, our data shows that the Foxn3 gene trap is not completely efficient 
in disrupting the expression of Foxn3 as the homozygous mutant tissues do express the 
wild type mRNA albeit at low levels (Figure 11).  This leaky expression of the native 
Foxn3 gene in the homozygous mutants further explains the partial lethality and 
segmental craniofacial defects of the homozygous mutants. More importantly, the 
hypomorphic alleles generated by gene trap mutants provide a novel opportunity to 
study the role of gene function(s) at the organismal level that provide data on the 
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developmental mechanisms involving heterotypic cell-cell interactions.  Such analyses 
are not possible with knock-out mouse models that suffer from disadvantages relating to 
embryonic lethality phenotypes or conditional mutants that are not amenable to 
functional studies involving cell and tissue specific heterotypic interactions during 
mammalian development. 
Expression Analysis of Foxn3 in Developing Embryo 
The β-galctosidase fusion protein present in the gene trap is advantageous as it 
allows visualization of the expression of Foxn3 during development. β-galactosidase 
breaks down X-Gal into 5-bromo-4 chloroindole which gives a bright blue color. Since 
the expression of β-galctosidase is correlated to Foxn3 expression, color change will 
only occur in specific tissue that express Foxn3. Figure 6 shows a specific expression of 
Foxn3 in the developing cranium and neural tube (brain, and spinal cord) of E13.5 
embryos. We were able to see high expression of Foxn3 in the eyes of E11.5 and E13.5 
embryos (Figure 6, and data not shown). It was during the examination of these embryos 
that we noticed many of the phenotypes previously associated with Foxn3 mutations. 
Figure 10 shows stereomicroscope images of wildtype and Foxn3 mutant E13.5 and 
E14.5 embryos. Comparison of littermate embryos shows microcephaly and cranium 
development defects in the mutant embryos compared to the wildtype embryos. 
Furthermore, the null embryos exhibit great reduction in eye size and eye migration 
defects which can be linked to cranium development defects. We could not attribute the 
reduction in eye size to reduction in cell proliferation, cell mass, or increased apoptosis; 
however, Schuff and his group indicated an increase in apoptosis in FoxN3 depleted X. 
laevis (122).  
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Foxn3‟s importance in development is demonstrated by the embryonic and post-
natal lethality of Foxn3 mutant mice (Table 1). Matings of Foxn3 heterozygous mice 
indicated 61% survival of the nullizygous offspring at day 1, which indicates 
developmental and embryonic lethality. However, at weaning (day 21), only 25% of 
nullizygous mice survived, which indicates more developmental and post-natal lethality 
in Foxn3 mutant mice. Most of the nullizygous mice died by post-natal day 3, and many 
of the nullizygous mice that survived exhibited a runting phenotype when compared to 
littermate heterozygous or wildtype mice (Figure 7). Measurement of the body mass of 
Foxn3 null mice indicated a three fold reduction when compared to wildtype littermates. 
An interesting pattern that emerged from expansion of the null mice colony was the 
increased survival of pups born from homozygous null mutants; we observed a high 
number of mice that survived through weaning which contrasted with the post-natal 
lethality (data not shown). Foxn3 expression of nullizygous postnatal day 1 mice 
generated from null crossings was much higher than the expression of similar mice 
obtained from heterozygous intercrosses (Figure 11a, and data not shown). This can be 
attributed to variable expressivity of a gene where individuals with the same genotype 
can display differing phenotypic characteristics (130).  
The underlying etiology of the post-natal lethality in Foxn3 mice was not 
determined, but previous work on X. laevis and our observations on average body mass 
may yield clues. Schuff and colleagues reported lost or deformed cranial nerves in X. 
laevis including hypoglossal and branches of the trigeminal nerve innervate the lower 
jaw. Moreover, they reported on the death of X. laevis embryos by stage 50 for reduced 
food intake. The loss of innervation of the lower jaw signifies reduced orifice function 
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and thus reduced food intake. The loss of lower jaw movement has more severe effects 
in a developing mouse as it initially has to suckle from the mother to feed and later chew 
solid food to feed and develop. The runting phenotype in our Foxn3 null mice can be 
explained by their reduced food intake due to reduced lower jaw function or 
misalignment of the jaw. We have also observed that some of our heterozygous and 
null mice die from abnormal growth of the incisors or malocclusion (data not shown).  
Perhaps the most significant finding of my work was the role of Foxn3 in 
mammalian craniofacial bone development. High resolution micro CT images of 8 day 
old and 11 day old wildtype and mutant pups shows reduced bone structure and density 
in the skull of Foxn3 mutant pups compared to wildtype littermates (Figure 6 A,B). mCT 
analysis also show absence or reduced bone structure on the oremaxillary area, the 
basisphenoid bone, the basioccipital bone, and the tympanic bone in 2 day old Foxn3 
mutant pups (Figure 6 E). We confirmed the bone density defect in Foxn3 mutant pups 
by histological evaluations of calvarial cross-sections, and we noticed severe reduction 
of the thickness of the calvaria and skull bones in the mutant pups (Figure 9). The 
underlying etiology of the reduced bone density in Foxn3 mutant mice could be 
attributed to variation in the osteoclast to osteoblast ratio in Foxn3 mutants or 
developmental defect in osteoblast differentiation leading to reduced calcification of 
cartilage (131). Therefore, we examined the expression profile of prototypical genes 
involved in osteogenesis that may have been deregulated in Foxn3 mutant mice. As 
shown in Figure 11, the expression of bone morphogeneic proteins 2,3,4,7 and Runx2 
were all down regulated in Foxn3 mutant skulls compared to wildtype littermates. Even 
more, the down regulation of these genes is consistent in Foxn3 mutant mouse 
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embryonic fibroblasts (MEFs) generated from other heterozygous crosses. These genes 
were tested because they have been shown to play a role in osteogenesis and also 
contained a Forkhead protein consensus sequence of [(A/G)(T/C)AAA(C/T)A] in their 
proximal promoter (132, 133).  
Craniofacial Development and FOXN3 
The mouse skull is composed of frontal, parietal, interparietal and occipital bones 
that have specifically evolved to surround and protect the brain.  These skeletal 
components receive lineage contributions from both the cranial neural crest cells and 
the paraxial mesoderm, both of which migrate to defined locations overlying the brain 
and subsequently differentiate into osteogenic and chondrogenic mesenchyme between 
embryonic stages E7.5 and E11.5 (132). The evolution of neural crest cells has been 
postulated as the foundation for the initial appearance and evolutionary expansion of 
vertebrates as it is unique to vertebrates (134). The skull vault primarily develops by 
intramembranous ossification, characterized by direct differentiation of the osteogenic 
mesenchyme into osteoblasts as opposed to endochondral ossification.  During skull 
development, the margins of each bone anlage are populated by highly proliferative 
osteoprogenitor cells thereby maintaining calvarial expansion (135). By E15.5 the 
individual skull bones have acquired their basic structure and are separated by sutures 
which are composed of fibroblasts and skeletal mesenchyme.  Calvarial bone growth 
and expansion is coordinated by the growth of the brain through continued production of 
the osteoprogenitors present within the suture (135). Several growth factors and 
transcription factors have been implicated in craniofacial and skeletal development 
(133, 136, 137). Of these, the fibroblast growth factors (FGF) and a number of 
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homeodomain proteins (Msx2, Dlx5, Engrailed 1, and Alx4) have been shown to 
regulate calvarial bone development (138, 139). Evidence indicates that the 
spatiotemporal expression of several of these growth and transcription factors and their 
interactions with each other regulate craniofacial skeletal development. The reduced 
expression of the osteogenic genes in the craniofacial tissues of the Foxn3 homozygous 
mutants suggests that the Foxn3 protein activates the expression of genes necessary 
for osteogenesis and plays a regulatory role in the craniofacial skeletal development.  
However, the molecular mechanism(s) of the aberrant expression of osteogenic genes 
in the Foxn3 mutants remain to be ascertained. Interestingly, the FOXN3 protein has 
been shown to associate with Sin3, a component of the Sin3/Rpd3 histone deacetylase 
complex (HDAC) in budding yeast and inhibit the activity of Sin3/Rpd3 HDAC complex.  
The Sin3 complex is targeted to specific promoter regions via Sin3 interactions with site-
specific DNA-binding proteins. Our data suggests that the loss of osteogenic gene 
expression in the Foxn3 mutants is potentially due to the loss of inhibition of Sin3 
complex that can in turn lead to deacetylation of histones within the promoters of the 
osteogenic genes resulting in their repression.  Nonetheless, a direct role for Foxn3 in 
the transcriptional activation of specific genes necessary for craniofacial development 
cannot be ruled out as the interaction studies have utilized heterologous systems 
(FOXN3 is not coded in the yeast genome). Furthermore, the interaction of Foxn3 with 
the transcriptional adaptor SKIP suggests that its role in the transcriptional regulation of 
its target genes might involve and be dictated by its interacting partners in a cell type 
and tissue specific manner. It is noteworthy that that the transcriptional activation and 
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repression functions of other Fox proteins have been shown to be cell-context 
dependent (92). 
Correlation of Foxn3 and Human Disease 
 Our assessment of the role of Foxn3 in developmental disease significantly 
correlates with congenital and developmental defects in human patients with deletions 
of chromosomal region 14q32.11 (Table 2). The most observable phenotypes were the 
growth retardation, eye deviations, scoliosis, and jaw abnormalities including 
malocclusions. Moreover, we observed abnormal kidney morphology and function as 
we performed necropsies on Foxn3 heterozygous and null adult mice, but we have not 
yet confirmed these observations by histological assessments. The remarkable overlap 
of phenotypes in Foxn3 mutant mice and human patients with FOXN3 locus deletions 
signifies the conservation of the role of Foxn3 in mammalian development and may 
provide an underlying mechanism of human disease. Indeed, expression of bone 
morphogenic protein 4 (BMP4) in mice has been shown to increase bone fractures 
healing time and bone density (140). Moreover, Wright and colleagues showed that 
muscle derived stem cells are capable of undergoing osteogenic lineage differentiation 
when transfected with BMP4-encoding retrovirus (141). This suggests that ectopic 
expression of BMP4 may be utilized to treat patients with craniofacial bone development 
defects or such application may be used to treat human patients with facial bone 
fractures or breaks. However, we have not yet evaluated the underlying molecular 




FOX Proteins, Cell-Cycle Regulation and Tumorgenesis 
Previous studies on FOX proteins and cancer 
The forkhead family of proteins has undergone an evolutionary expansion in 
higher eukaryotes and mammals compared to C. elegans and Drosophila (142). This 
allows adaptation of FOX proteins to the increased developmental and tissue 
complexity required in higher organisms. FOX members have been shown to play 
diverse roles in development, immune system, apoptosis, cell cycle control, cancer, and 
invasion of metastatic tumors (143). FOX proteins are terminal effectors for many 
signaling pathways, and mutations in FOX proteins perturb proper activation of these 
pathways to maintain homeostasis. Correlation of gene function can be made through 
in-vivo studies on rodent models because all human FOX genes have orthologues in 
mouse, except for FOXD family which has one member (Foxd1) in mouse but seven 
members in humans due to a recent duplication (144). Mutations in several Fox 
subfamilies (FoxA, FoxC, FoxL, FoxM, FoxO, and FoxP) have been shown to promote 
tumorogenesis in mouse models in a specific or redundant form. FoxC proteins are 
involved in the development of vascular system, and are correlated to cancer through a 
role in vascular angiogenesis (142). FoxL1 is expressed in the messenchyme of the GI 
tract and null mutation to Foxl1 reduced epithelial cell proliferation due to disrubtion of 
the Wnt pathway in this organ. Furthermore, Apc+/Min;Foxl1-/- mice showed higher tumor 
load in the colon compared with APC+/Min;Foxl1+/+ and Apc+/Min; Foxl1+/- mice thus 
showing synergistic effect of mutations in adenomatous polyposis coli (APC) gene and 
Foxl1. This suggests that some FOX genes can be deregulated during tumorogenesis 
but may not be able to initiate it on their own. There are a few FOX family members that 
61 
 
regulate cell-cycle processes and can thus be considered true tumor suppressor genes 
or proto-oncogenes (93). 
FOXM family 
FOXM1 is a proliferation-associated transcription factor that promotes S-phase 
entry and proper execution of mitosis in rapidly dividing cells (99, 145). FOXM1 gene is 
up-regulated in pancreatic cancer and basal cell carcinoma due to the transcriptional 
regulation by Sonic Hedgehog (SHH) pathway (142). FOXM1 has splice variant proteins 
that play a crucial role in mitosis and G1/S phase and G2-M cell-cycle progression 
through regulation of different proteins. Foxm1b transcription factor is essential for liver 
development, hepatoblast regeneration and hepatocyte mitosis during liver 
morphogenesis. Conditional deletion of Foxm1b results in diminished DNA replication 
and failure of hepatoblast to enter mitosis due to decreased levels of Polo-like kinase 1 
and Aurora B kinase, which regulate proteins during mitosis (145). Foxm1b also 
regulates the induction of c-Myc, c-Fos, and cyclin-B, all associated with cell 
proliferation and S-phase entry (145). The splice variant FOXM1a binds the same DNA 
sequences as FOXM1b, but does not trans-activate genes (146). In human studies, the 
FOXM1 gene is located on the chromosomal locus 12p13, a region typically amplified in 
breast adenocarcinomas, head and neck squamous cell carcinomas, and cervical 
squamous carcinomas. This region also contains CDKN1B (encodes p27), so it remains 
possible that FOXM1 may not initiate tumorogenesis, but rather enhancing its 





The FOXO family is considered to function as a tumor suppressor family through 
promoting cell cycle arrest and apoptosis. FOXO family expression varies between cell 
types or organs. FoxO1 is highly expressed in adipose tissue, while FoxO4 is in muscle 
and FoxO3a in liver and FoxO6 is exclusively in brain. All FoxOs bind to the same 
FOXO recognition element 5‟-(G/C)(T/A)AA(C/T)AA-3‟ and can essentially regulate the 
same set of genes through binding of this motif. The FOXO family plays a dual role as 
transcriptional activators and transcriptional repressors, and they exhibit nuclear 
shuttling by having nuclear localizing sequence (147, 148).Initial correlation of FOXO 
family with cancer was revealed in translocations in tumors especially in alveolar 
rhabdomyosarcoma where a translocation in (2;13) and (1;13) results in PAX3-FoxO1 
and PAX7-FoxO1 fusion proteins (142). Since then, studies in mice have revealed that 
single FoxO mutant mice form mostly neoplasias while triple mutants (FoxO1, FoxO3A, 
FoxO4) can induce Myeloid-lymphoid leukaemia (MLL) and thymic lymphomas, thus 
exhibiting redundancy and compensation in the FoxO subfamily (149). FOXO family 
protein regulate cell cycle arrest and apoptosis by regulating the expression of cyclin-
dependent kinase (Cdk) inhibitors p27Kip1 and p21Waf1 or repressing the expression of 
Cyclins D1 and D2 (150). FOXO family proteins are involved in glucose homeostasis 
and activation of multiple insulin-responsive genes; FOXO are targets for PI3K-Akt 
mediated phosphorylation to regulate glucose homeostasis (84). Phosphorylation of 
FOXO family protein by Akt protein kinases causes the retention of FOXO proteins in 





The FOXP family members have been implicated to function as either oncogenes 
or tumor suppressor genes, depending on various contexts. FOXP family members 
have been shown to play roles in immune response regulation, B-cell development, 
tumorogenesis, and neuronal development (151-153). A well-known member of this 
family is FOXP2, which is associated with many developmental disorders most notably 
speech and expressive language impairments, but has not been associated with cancer 
(154). FOXP1 was the first member of this family to be cloned, and differently from 
FOXO family members, is expressed in all tissues. In several subtypes of B-cell non-
Hodgkin lymphomas, high-level FOXP1 protein expression is achieved through 
recurrent chromosome translocations involving the FOXP1 locus and is a marker for 
poor prognosis for patients (155). Alternative splicing leads to N-terminal truncations of 
FOXP1 and over expression of short oncogenic isoforms of FOXP1 in diffuse large B-
cell lymphoma (DLBCL) (153). Alternatively, nuclear expression of FOXP1 in breast 
tumors was associated with improved patient survival, and thus was predicted to 
function as a tumor suppressor protein (156). FOXP1 and FOXP2 have also been 
shown to act as repressors on genes involved in lung morphogenesis (157). FOXP3 is 
the last member of the FOXP family, and it‟s been linked to the immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) (158). FOXP3 attenuates 
the expression of cytokine necessary in T cell development by repressing the activity of 
nuclear factor of activated T-cells (NFAT) (159). FOXP3 is a transcriptional repressor of 
the onco-protein c-Myc, and somatic inactivation or deletion of X-linked FOXP3 has 
been observed in patients with prostate cancer (160). Additionally, FOXP3 loss of 
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expression is observed in aggressive breast cancer in humans, and predisposes mice 
to breast cancer (93).   
FOXN3 and cancer 
Comparative real-time RT-PCR studies have shown that FoxN3 (Ches1) is 
under-expressed in 46% of human oral squamous cell carcinoma samples, and its 
expression was decreased by 15 fold in OSCC tissue with a concomitant over-
expression of CDK1, NPM and NDRG1 (161). Ches1 and CDK1 were predicted to be 
linked in a regulatory network during tumorogenesis (161). Ches1 was also under-
expressed in clear renal cell carcinomas (cRCC) compared to normal tissue (162). In a 
study of laryngeal carcinoma markers, Ches1, along with ADAM-12, CDK2, and KIF-14 
were found to be good specific markers for this cancer (163). The down-regulation of 
FOXN3 in malignant tissues, along with the finding that human FOXN3 recruits SKIP to 
repress transcription, indicate that certain oncogenes regulated by FOXN3 may be over-
expressed in cancer cells due to decreased FOXN3 levels (116). To further investigate 
a possible role for FOXN3 in initiating tumorogenesis, we analyzed the heterozygous 
and some homozygous Foxn3-mutant mice for survival and tumor formation over two 
years time period.  
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Materials and Methods 
Generation of Foxn3 mutant mice 
Foxn3 mutant mice were generated and maintained as previously described (124). 
Upon signs of morbidity, mice were euthanized and organs were harvested and saved 
in 10% formalin solution. Wild type, heterozygous mutant, and nullizygous mutant mice 
(n= varies) were irradiated with X-ray radiation (7 Gray, 2 Gray/week) beginning at 4 
weeks old. Upon signs of morbidity, mice were euthanized and necropsy was performed 
to check for tumors.  
Generation of Mouse Embryonic Fibroblasts. 
MEFs were derived from 13.5-day-old Foxn3+/+, Foxn3+/m and Foxn3m/m embryos. 
After removal of the intestinal organs, each embryo was washed with PBS (Gibco) and 
minced using 18 gauge needles. Cells were cultured in Dulbecco‟s modified Eagle 
medium with high glucose (HyClone, South Logan, Utah, USA) supplemented with 2mM 
L-glutamine, 1X antibiotic-antimycotic, 1μl/ml of fungizone (Invitrogen, Carlsbad, CA) , 
and 15% heat-inactivated fetal bovine serum (Gibco). Primary cells were frozen in 
aliquots after the first passage.  
Immortalization of Foxn3 MEFs 
Foxn3 +/+, Foxn3 +/m, Foxn3m/m MEFs were immortalized by transforming the cells 
with SV-40 (simian vacuolating virus 40) large T antigen containing plasmid 
pBSSVD2005. Primary Foxn3 passage 2 MEFs were plated at 50% confluency in a 
100mm plate and cells were transiently transfected with pBSSVD2005 using Turbofect  
reagent (Fermentas, Glen Burnie, MD) according to the manufacturer‟s instructions. 
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When the cells were just confluent, they were split at a dilution of 1/10. The cells were 
continued to be split at 1:10 dilutions till passage 5. This type of splitting ensured a 
strong negative selection against non-transformed cells. 
Clonogenicity Assay 
SV-40 immortalized Foxn3 +/+, Foxn3 +/m, Foxn3m/m MEFs (2.5X103) cells were 
seeded in complete media and treated with 10 J/m2 UV radiation or exposed to 4 Gy 
dose of X-ray radiation 24hrs after seeding. After ~8 -10 days, the plates were stained 
with coomassie blue and colonies were counted using a stereomicroscope. The 
colonies from the various treatments were normalized to the untreated control. For each 
treatment, the cells were plated in four 60mm2 plates. The whole experiment was 
repeated twice using two independently derived cell lines.  
RNA Interference Transfection 
RNAi oligonucleotides were obtained from IDT DNA (F-LUC-Si, FOXN3) and 
resuspended in nuclease-free water to a concentration of 40µM. HCT116 cells were 
plated in 60mm-well plates in DMEM media containing 10% fetal bovine serum to give 
30–50% confluence. Transfection of the RNAi oligonucleotides was performed using 
Trifectin (IDT-DNA) to result in a final RNA concentration of 40 nm. The cells were 
harvested at different time points and lysed in BE lysis buffer plus 1mM PMSF (40mM 
NaCl, 20mM Tris-HCl pH 7.8, 2mM MgCl2, 0.5% NP40, Benzonase (Novagen, 
250U/mL) for Western blot analysis. siRNA sequences were:  
F-Luc si: 5'-rGrCrA rUrArU rCrArA rArGrC rArCrA rUrCrA rGrGrU rCrCA C-3' 




Foxn3: 5- rGrCrA rUrArU rCrArA rArGrC rArCrA rUrCrA rGrGrU rCrCA C -3 
          5'-rGrUrG rGrArC rCrUrG rArUrG rUrGrC rUrUrU rGrArA rUrGrC rCrU-3' 
Western Blot 
HCT116 cells were scraped in phosphate-buffered saline (PBS), pellet at 1‟400 RPM, 
and lysed in BE lysis buffer plus 1mM PMSF (40mM NaCl, 20mM Tris-HCl pH 7.8, 2mM 
MgCl2, 0.5% NP40, Benzonase (Novagen, 250U/mL). Cell lysates were mixed with 
reducing Laemmli sample buffer, separated on 8% or 12% SDS–polyacrylamide gels 
and transferred onto PVDF membranes (Thermo scientific). Membranes were blocked 
at room temperature for 2 hours in TBS-Tween (100mM Tris-HCl, 200mM NaCl, 0.1% 
Tween 20) with 5% milk, and incubated with primary antibody overnight at 4oC or at 
room temperature for 2 hours. After washing with TBS-T, membranes were incubated 
with horse radish peroxidase-conjugated secondary antibody for 1 hour at room 
temperature in TBS-T containing 2% milk. Signal was visualized with the Super Signal 
chemiluminescent reagent (Thermo scientific).  
 
Reagents and Antibodies 
Cell culture reagents were obtained from the following sources: fetal calf serum and 
Antibiotic-Antimycotic (Gibco, Invitrogen). Antibodies were obtained from the following 
sources: FoxN3 (Santa Cruz Biotechnology, Santa Cruz, CA; sc-54257), Cyclin-B1, 




Statistical analyses and survival curves 
Standard error, mean and P-values were determined using the statistics software from 
Microsoft Excel. Kaplan–Meir survival curves were generated and analyzed with Prism 




3.1. Characterization of tumorogenesis in Foxn3 mice 
 The mutant offspring that survived beyond the perinatal stage did not show any 
overt developmental abnormalities except for a pronounced reduction in size at weaning 
but was less apparent in 3–4 months old mice. However, after 7–12 months of age, the 
heterozygous and homozygous mutant mice began to exhibit weight loss, lordokyphosis 
(hunch-back spine) and loss of vitality. Survival analysis showed drastic reduction in the 
lifespan of the Foxn3 heterozygous (+/m) and homozygous (m/m) mutant mice (median 
lifespan of 80 weeks for heterozygous, median lifespan of 64 weeks for homozygous) 
(Figure 12). Histological examination of organs harvested from morbid mice showed that 
a majority of the mice were succumbing to splenic or thymic lymphomas with a minor 
fraction of adenomas and sarcomas (data not shown). The earliest incidence of 
lymphomas in the mutant mice was at 26 weeks of age. 50% of nullizygous mutants 
(8/16) exhibited spontaneous tumor formation and 43% in heterozygous mutants 
(13/30). In comparison, only 25% of wild-type mice were diagnosed with a tumor during 
the analysis period (4/12). Wild-type mice also develop lymphomas as a function of age, 
and such tumors account for about 5–20% incidence as reported for mice of various 




Figure 12. Survival Curve of Foxn3 mice. Kaplan–Meier survival curves of Foxn3 mutant and wild-type 
littermates (n=20 +/+ , n=47 +/m , n=16 m/m). The percentages of survival are plotted as a function 
of age in weeks. Animals were monitored for tumors, morbidity or spontaneous death over a 
period of 105 weeks. Of the animals analyzed for each group (numbers mentioned above), 40 of 
the heterozygous mutants died, all 16 of the nullizygous mutants died in comparison with 9 for the 
wild-type controls during a period of 2 years. The differences in the lifespan of wild type and 
mutant animals were statistically significant (p<0.0001). All mice were of mixed inbred 
C57BL/6X129/Sv background. 
 
Additionally, we wanted to assess whether Foxn3 plays a role in DNA damage response 
or cell-cycle progression in mice. Therefore, we treated 4 weeks old wild type (WT), 
heterozygous mutant (Het) and homozygous mutant (Null) with 7 Gray X-ray radiation 
(1.75 Gy/week, 4 weeks) and checked for signs of lethargy, tumor formation, or death. 
Survival analysis showed drastic reduction in the lifespan of the Foxn3 heterozygous 
(Het) and homozygous (Null) mutant mice (median lifespan of 28.28 weeks for Het, 
median lifespan of 28.84 weeks for Null) compared to wild-type littermates (median 
lifespan of 60 weeks) (Figure 13). The earliest incidence of lymphomas in the mutant 
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mice was at 13 weeks of age. The difference in lifespan between the mutant animals 
and wild-type littermates was statistically significant (P<0.01), but there was no 
statistical significance between heterozygous and nullizygous mutant animals (similar 
median lifespan).   























Figure 13. Survival analysis of Foxn3-deficient mice after IR treatment. Kaplan–Meier survival curves 
of Foxn3 mutant and wild-type littermates (n=9 Wt , n=13 Het , n=14 Null). The percentages of 
survival are plotted as a function of age in weeks. Animals were monitored for tumors, morbidity 
or spontaneous death over a period of 66 weeks. Of the animals analyzed for each group 
(numbers mentioned above), all 13 of the heterozygous mutants died, all 14 of the nullizygous 
mutants died in comparison with 6 for the wild-type controls during a period of 66 weeks (all 
animals were terminated at 66 weeks). The differences in the lifespan of wild type and mutant 
animals were statistically significant (p<0.01). All mice were of mixed inbred C57BL/6X129/Sv 
background. 
 
3.2. Impaired DNA repair in Foxn3 deficient MEFs 
Transformation of normal rodent cells into tumorogenic cells requires the 
deregulation of genes that control cell growth and differentiation. Several genes can be 
upregulated in combinations to produce this phenomenon (i.e. activated Ras and Myc, 
activated Ras and activated E1A, simian virus SV40 large T antigen) (165). We used 
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SV40 large T-antigen transformed Foxn3 MEFs to perform a clonogenicity assay to test 
the long term survival of MEFs after DNA damage (UV and X-ray radiation). SV40 
transformed Foxn3 mutant MEFs were strikingly hypersensitive to UV and X-ray 
radiation treatment compared to wildtype MEFs (Figure 14). These observations signify 
that immortalization of Foxn3 heterozygous and homozygous mutant MEFs makes them 
vulnerable to UV and X-ray radiation DNA damage, which in turn reduces their 
clonogenic survival.  
  
 
Figure 14. Clonogenicity assay of Foxn3 MEFs. SV40 transformed wildtype (+/+), heterozygous (+/m) 
and homozygous (m/m) MEFs were seeded and treated with 10 J/m2 UV radiation or 4 Gy dose of 
IR. Colonies were counted after 8-10 days. The percentage of untreated cells was set at 100%. 
Error bars represent SD values for quadruplet samples. Heterozygous and homozygous mutant 






































3.3. FOXN3 deficiency deregulates cell-cycle regulatory proteins 
RNA interference was effective in reducing FOXN3 protein levels in HCT116 
cells. We checked the protein levels of cell-cycle progression proteins including CDK1 
(CDC2) and CDK2, Cyclin-B1, Cyclin D1, and Retinoblastoma for any deregulation of 
expression due to loss of FOXN3. The levels of Cyclin-B1 and CDK2 proteins were 
reduced in FOXN3 deficient cells compared to F-Luc controls (Figure 15). Meanwhile, 
Cyclin-D1, Cdc2 (CDK1), and Rb protein levels were not changed due to FOXN3 
deficiency, indicating a specific effect of FOXN3 on cell cycle progression proteins. 
Beta-Tubulin indicates equal loading of cell lysates.  
 
Figure 15. Western blot analysis of cell-cycle progression proteins after RNAi-mediated knockdown of 
FOXN3. FOXN3-specific RNAi was efficient in reducing FOXN3 levels in HCT116 cells 48 hours 
after transfection. Cyclin-B1 and CDK2 proteins were reduced in FOXN3 deficient cells, 
meanwhile, Cyclin-D1, Cdc2 (CDK1), and Rb protein levels were not changed due to FOXN3 




 The data accumulated thus far indicates a role for Foxn3 in tumorigenesis as 
heterozygous and homozygous mutant animals exhibit a decreased lifespan and 
increased spontaneous tumor susceptibility. The majority of the mice succumbed to 
splenic or thymic lymphomas with some cases of adenomas and sarcomas. This is the 
first mouse model that studies the role of Foxn3 in initiating tumorigenesis in mammals. 
All previous reports have shown deregulation of FOXN3 expression in human patients‟ 
cancer samples, but never a role for Foxn3 as a true oncogene or tumor suppressor 
gene (161). Additionally, Foxn3 deficiency can enhance tumorigenesis in mice that have 
been treated with ionizing radiation (IR) to initiate tumors. Exposure of mice to IR leads 
to DNA double stand breaks (DSB‟s), which if left unresolved, can lead to 
rearrangements and aberrations of chromosomes, thus leading to genomic instability 
and initiate cancer formation (28, 166). This data suggested a possible role for FOXN3 
in DNA repair or regulation of cell-cycle progression. To investigate the underlying 
mechanism of Foxn3-mediated tumorogenesis, we performed a clonogenicity assay to 
test the long term survival of Foxn3 mutant MEFS after DNA damage. The colony 
forming competency of Foxn3 mutant MEFs was greatly compromised after UV and X-
ray radiation treatments, which may suggest a role for Foxn3 in the DNA damage repair 
pathway. However, more experiments are required to further prove the role of Foxn3 in 
DNA damage repair. Interestingly, we have performed a cell proliferation assay and 
results indicate a tremendous proliferation capacity for the heterozygous MEFs, while 
the homozygous and wild type MEFs maintain the same growth kinetics over the same 
time (data not shown). However, we have not been able to generate three independent 
MEF cell lines to cover the biological replicas to prove this data.  
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To determine a functional mechanism for FOXN3 in tumorogenesis and cell-cycle 
regulation or DNA repair pathways, we checked the levels of specific cell-cycle 
checkpoint proteins that have either been reported to be deregulated in FOXN3-
deficient cancer samples, have a Forkhead Box binding site in their promoter, or are 
known interaction partners of checkpoint proteins. We were able to shown that cyclin- 
dependent kinase 2 (CDK2) and Cyclin-B1 levels in FOXN3-deficient HCT116 cells 
were lower than their Firefly-luciferase (control) transfected cells. Meanwhile, other 
proteins levels like Cyclin-D1, Retinoblastoma, and Cdc2 (CDK1) were not changed due 
to FOXN3 deficiency. This contradicted a previous report which showed con-committal 
reduction of FOXN3 and CDK1 in oral cancers (167). Arguably, analysis done on oral 
cancer samples can have different driver mutations that can perturb other pathways 
leading to deregulation of CDK‟s and other checkpoint proteins (168). Meanwhile, our 
system ascertains the expression of proteins due to reduction of FOXN3 only in a more 
controlled experimental setting.  Yet, a deeper look into the redundant and cooperative 
mechanisms of cyclins and CDKs can shed some light on this contradiction.  
Regulation of the cell cycle is an essential process in maintaining cellular 
homeostasis and regulation of cell proliferation. At the epicenter of cell-cycle control are 
heterodimeric protein kinases composed of a catalytic subunit, the Cyclin-dependent 
kinase (Cdk), and a regulatory subunit known as Cyclin (169). Each family of cyclins 
binds to a specific Cdk, forming a complex that is active at a specific phase of the cell 
cycle. Progression of the cell-cycle is driven by sequential activation of several Cyclin-
dependent kinases (Cdk), but mainly Cdk4, Cdk6, Cdk2 and Cdk1. Cues to initiate cell 
division come from mitogenic factors (IGF-1, MAPK pathway) to induce expression of 
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cyclin D and thus stimulate the activities of its binding partners Cdk4 and Cdk6 (170). 
Increasing accumulation of cyclin D/Cdk4, Cyclin D/Cdk6 and cyclin E/Cdk2 complexes, 
along with proliferating cell nuclear antigen (PCNA) coordinate DNA replication and 
transition the cell into S phase entry. G2/M transition is regulated by cyclin A/Cdk2 and 
cyclin B/Cdk1 complexes. Additional factors termed „cyclin-dependent kinase inhibitors‟ 
(CKIs) further control cell cycle progression; p27KIP1 and p21CIP1are examples of CDKI‟s 
that bind to CDKs and prevent their activation. Some of these CDKI‟s are controlled by 
tumor suppressor proteins like p53, which can arrest cell cycle progression at any stage 
to ensure proper proliferation (171). Recent studies in different Cdk knockout mice have 
shown redundancy in Cdk function and compensation by other complexes to promote 
cell division. Mice lacking Cdk4 and Cdk2 complete embryonic development but die 
shortly thereafter presumably; however, conditional ablation of Cdk2 in adult mice 
lacking Cdk4 does not result in obvious abnormalities (172). Cdk2 and Cdk4 are 
required to phosphorylate Retinoblastoma (Rb), a protein essential for G1/S cell cycle 
progression. Additionally, Cdk2 and Cdk4 cooperatively regulate the expression of Cdc2 
(CDK1), which cannot compensate for the loss of CDK2 during embryogenesis (170). 
Recent work has also shown that Rb/Cdk2/Cdk4 triple mutant MEFs sustain enhanced 
S-phase entry and proliferation rates similar to wild type (173).  
Taken together, the loss of CDK2 could have been compensated by CDK4 or RB to 
progress cells through the G1/S transition. Meanwhile, Cyclin-B1 interacts with CDK1 at 
G2/M during transition into G2/M phase of the cell cycle and brings the onset of mitosis 
(174). G2/M phase possesses a complex regulatory network of proteins that ensure 
proper entry into this phase and proper mitosis. FOXN3-mediated loss of cyclin-B1 can 
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potentially drive cells into G2/M without any regulatory input from CDK1, thus explaining 
the cell proliferation seen in Foxn3 heterozygous mutant MEFs. Additionally, a Cyclin 
A/Cdk2 complex regulates the activation of Cdk1 and Cdc25 (175). This provides 
another potential link to the role of FOXN3 in regulating the activation of CDKs and 




Chromatin Remodeling Proteins and The Role of CHD2 in Tumorgenesis 
Chromatin and Nucleosome Dynamics 
DNA in the eukaryotic cell is organized into a hierarchical structure called 
„chromatin‟. Nucleosomes are the fundamental units of the chromatin and they consist 
of 146 base pairs of DNA wound around a histone octamer. The histone octamer is a 
positively charged protein unit that wraps the negatively charged DNA around it to 
condense the DNA. The histone octamer consists of two molecules of each of the 
histones H2A, H2B, H3, and H4 (176). This initial nucleosome organization forms a 10-
nm fiber known as “beads-on-a-string”. The binding of the linker histone H1 to the 10-
nm fiber allows for organization of the nucleosome arrays into a 30-nm chromatin fiber 
(177). Higher-order compaction of DNA involves the „structural maintenance of 
chromosomes‟ proteins (SMC) which include condensin and cohesin (178). Intrinsic 
functions of the cell, such as DNA replication, transcription, and DNA repair require 
accession of DNA sequences by DNA binding factors at proper regions and during the 
appropriate times, however the compaction of DNA into chromatin makes it inaccessible 
to such factors. To overcome this problem, a multitude of factors including histone 
modifying enzymes and chromatin remodeling complexes work together enhance 
accessibility of DNA regions to their specific factors. These chromatin modifying 






Histone modifying proteins 
Histones, the protein component of the nucleosome, form two H2A-H2B dimers and one 
H3-H4 tetramer that form the two nearly symmetrical halves of the histone octamer. 
Histones fold into a helix-turn-helix region that composes the core of the histone and 
also contain an N-terminal tail that protrudes outside the compact histone core. 
Histones are subjected to posttranslational modifications at their N-terminal tails that 
affect the affinity of DNA wrapping around the histone octamer (179). These post-
translational modifications include methylation, acetylation, phosphorylation, 
ubiquitination, SUMOylation, ADP-ribosylation, and other modifications. These 
modifications regulate the DNA at a „higher level‟ than the underlying DNA sequence; 
the term “Epigenetics” or “histone code” has been given to these modifications (180). 
The two best-studied modifications are methylation and acetylation.  
Histone methylation of arginine and lysine residues is a major determinant for 
formation of transcriptionally active and inactive regions of the genome as well as the 
state of chromatin compaction. Arginine mono or di-methylation of histones H3 (Arg2, 
17, 26) and H4 (Arg3) promotes transcriptional activation and a more loose chromatin 
(181-183). This methylation is mediated by the protein arginine methyltransferases 
(PRMTs) family that includes the co-activators PRMT1 and CARM1 (PRMT4) (184). In 
contrast, histone lysine methylation is a more diverse and a better studied histone 
modification. Lysine methylation is associated with both transcriptional activation as in 
histone H3 (Lys4, 36, 79) and silencing as in histone H3 (Lys9, 27) and histone H4 
(Lys20) (185). Tri-methylation of histone H3 (Lys9, 27) is associated with 
heterochromatin, a region of highly compacted DNA with no active transcription. 
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Additionally, methylated lysine histone tails can recruit proteins like HP1 (utilizing their 
chromodomains) to propagate the methylation pattern to nearby histones, leading to 
heterochromatin formation. The majority of lysine methyl-transferases identified thus far 
contain a conserved catalytic SET domain originally identified in the Drosophila 
Su[var]3-9, Enhancer of zeste, and Trithorax proteins (186). Conversely, methylated 
histones can become demethylated if acted upon by a group of enzymes that include 
the amine oxidase LSD1 (lysine specific demethylase 1), hydrolase JmjC (Jumonji) and 
the arginine deaminase PAD4 (peptidyl arginine deiminase 4) (187). These enzymes 
can remove methylated lysine or arginine residues (mono or di-methylated) and thus 
can act as transcriptional repressors or activators, depending on the demethylated 
residue.  
Histone acetylation of lysine residues is another major epigenetic marker typically 
associated with active transcription and loose compaction of DNA around the histone 
octamer. Acetylation neutralizes the overall positive charge of the lysine residue, thus 
reducing the affinity and weakening the binding between negatively charged DNA and 
positively charged histones. Acetylation of histone H3 (Lys9) and histone H4 (Lys5, 8, 
12, 16) are known markers for euchromatin, a region of lightly compacted chromatin 
associated with active transcription (188). Not only does histone acetylation loosen the 
DNA compaction, but it also helps recruit bromodomain-possessing proteins involved in 
transcription. Acetylation of histone H3 (Lys9, 14) recruits the TFIID of the RNA 
polymerase, while acetylation of histone H4 (Lys8) recruits the SWI/SNF complex (189). 
Histone acetyl-transferases (HAT) are the family of enzymes responsible for histone 
acetylation at lysine residues. The transcriptional coactivator families MYST, 
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Gcn5/PCAF, and CBP/p300 compose the main three families of HAT, but are also 
capable of acetylating other transcription factors like p53 (64, 190). Histone 
deacetylases (HDACs), on the other hand, remove the acetyl group from lysine residues 
of histones and promote compaction of DNA. The transcriptional co-repressor complex 
Mi2/NuRD, mSin3a, and NCoR/SMRT recruit HDAC1, 2, and 3 respectively to de-
acetylate histones and compact the genome (191, 192).   
ATP-dependent chromatin remodeling factors 
 Nucleosomes can be actively modified through ATP-dependent protein 
complexes that utilize the energy from ATP hydrolysis to physically slide or remove 
histones and nucleosomes (193). The common feature of the ATP-dependent chromatin 
remodeling complexes is a highly conserved SNF2-related ATPase domain present in 
four main classes and variations: The switching/ sucrose non-fermenting (SWI/SNF), 
imitation switch (ISWI), INO80, and chromodomain helicase DNA binding (CHD), which 
will be discussed in greatest detail. The INO80 complex is a conserved protein complex 
composed of the Ino80 ATPase subunit, two AAA+ ATPases (Rvb1/2), Actin and its 
related proteins Arp4, 5, and 8 (194). The Ino80 ATPase subunit provides the energy for 
chromatin remodeling through nucleosome sliding. The INO80 complex interacts with 
transcription factor Ying Yang 1 (YY1), linking INO80 to both activation and repression 
of transcription. Additionally, INO80 is recruited to DNA double stand breaks (DSBs) in 
yeast through interactions of its Arp4p and Nhp10p subunits with the phosphorylated 
H2AX (γ-H2AX) histone variant present at the DSB site. The Drosophila ISWI is another 
member of the SNF2-related family of ATPases, and it is the catalytic core of three 
chromatin remodeling complexes: NURF, CHRAC, and ACF (195). Residues 16-19 of 
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histone H4 have been shown to be required for stimulation of ISWI ATPase activity, 
which in turn repositions nucleosomes along DNA in cis (196).  
The Swi2/Snf2 is the third class of SNF2-related ATPases and is the main 
catalytic subunit of the yeast SWI/SNF complex. SWI/SNF protein complex interacts 
with GAL4, a sequence-specific transcription factor, and mediate transcription in yeast 
(197). Homologous subunits to the ATPase domain have also been identified in S. 
cerevisiae (the RSC complex), Drosophila (BAP and PBAP), and at least two 
complexes in mammals including the BRG1-associated factor complex (BAF), and the 
polybromo BRG1-associated factor complex (PBAF; homologous to S. cerevisiae Rsc) 
(198, 199). While SWI/SNF complex mediates transcriptional activation in yeast, 
mammalian SWI/SNF complexes contribute to both repression and activation. During 
mammalian T lymphocyte development, BRG1 is required to activate CD8 expression 
and silence CD4 simultaneously (200). The flexibility of SWI/SNF complexes lies within 
their ability to utilize ATP-dependent chromatin remodeling while also recruiting histone 
deacetylases (HDACs), thus removing the transcriptional activating acetyl marks from 
histone tails. ATP-dependent chromatin remodeling involving SWI/SNF complexes is 
initiated through binding of the complex to nucleosomal DNA, followed by disruption of 
histone-DNA binding, and ATPase subunit mediated translocation of DNA from histones 
(198). This forms a DNA loop that can then be propagated through sliding or removal of 
adjacent nucleosomes to generate stretches of DNA that are more accessible to DNA 




The CHD family of chromatin remodeling proteins 
The chromodomain helicase DNA-binding proteins (CHDs) are an evolutionary 
conserved family of proteins associated with chromatin remodeling (201).  Members of 
the CHD family of proteins are present in all eukaryotic organism; nine CHD family 
members have been characterized in vertebrates. The CHD family is divided into three 
subfamilies depending on the presence of additional motifs and the chromodomain 
subclass. CHD1 and CHD2 belong to Subfamily I; CHD3 and CHD4 belong to 
Subfamily II, while CHD5 through CHD9 belong to Subfamily III. CHD family proteins 
are characterized by the presence of two chromodomains (Chromatin organization 
modifier), DNA-dependent SNF2-related ATPase domain, DNA-binding domains (HMG-
1, PHD Zn-finger) and C-terminal helicase domain. The chromodomain is a 40-50 
amino acids motif that binds to methylated lysine residues in the N-terminal tails of 
histones, thus recognizing epigenetic marks laid out by histone modifying enzymes 
(202). This domain is present in many proteins involved in chromatin remodeling 
(Drosophila heterochromatin protein 1, HP1), heterochromatin formation (Polycomb), 
and regulation of gene expression (RBP1) (203). The chromodomain is formed through 
a hydrophobic core and hydrophobic groove required for interaction with tri-methylated 
lysines and dimerization. The SNF2-related ATPase domain is a ~400 amino acids motif 
that possesses an N-terminal ATP-hydrolysis domain and a C-terminal transduction 
domain. Proteins that possess SNF2-related ATPase domain can disrupt nucleosomes 
by either dissociating and/or repositioning (RSC and SWI/SNF), generating ordered 
arrays of nucleosomes (Chd1 and ISWI), or facilitating the exchange of histones with 
histone variants of a nucleosome (INO80 and SWR1) (204). CHD proteins mediate 
chromatin remodeling by first binding to either DNA using their DNA-binding domain, or 
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methylated histone tails using their chromodomain, and then activate their SNF2-related 
ATPase/helicase domain (205). Activated ATPase domain facilitates ATP-dependent 
translocation of the protein along DNA, thus generating force that can be directed into 
arranged movement or destabilization of nucleosomes. 
CHD Subfamily I 
CHD subfamily I consists of two proteins: CHD1 and CHD2. Murine CHD1 
protein was isolated from cDNA libraries of mouse lymphoid cell mRNA and encodes a 
197-kDa protein characterized by the presence of chromodomain, a SWI2/SNF2 like 
helicase domain, and its ability to bind immunoglobulin promoter sequence (206). CHD1 
homologues were identified in most eukaryotic organisms with conserved domain 
across all species. CHD1 has a pair of N-terminal chromodomains followed by SNF2-
related ATPase/helicase domain, a C-terminus helicase domain, and a Myb-related 
DNA binding domain (201, 207). The human CHD1 is 95% homologous with murine 
Chd1at the amino acids level and its chromodomains have been shown to bind 
methylated lysine 4 in the histone H3 tail (H3K4) (204). This provides a mechanism that 
targets CHD1 to transcriptionally active chromatin, as marked by trimethylated H3K4 
(208). However, the two chromodomains of yeast Chd1 cannot bind to methylated H3K4 
peptides, and in Drosophila the chromodomains are not required for the chromatin 
localization of CHD1. The other possible mechanism of CHD1 localization to sequence 
specific regions lies within its C-terminal DNA-binding domain. Studies on murine Chd1 
identified a region of ~250–300 amino acids in its C-terminus that are required for 
proper association with DNA and chromatin (204). Further analysis of the domain 
revealed two main motifs similar to the SANT domain (SWI3, ADA2, NCoR, and TFIIB) 
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and the SLIDE (SANT-like ISWI domain) domain. The Myb DNA binding domain is a 53 
amino acids domain that forms a helix-turn helix motif characterized by the presence of 
aromatic residues (209).  
CHD1 has been shown to interact or be a component of many protein complexes 
in depending on the organism. CHD1 has been shown to interact at the Drosophila‟s 
polytene chromosome with the nuclear protein structure-specific recognition protein 1 
(SSRP1), which plays a role in homologous recombination-mediated DNA damage 
response (210). The majority of Chd1 studies were conducted in S. Cerevisiae, where 
Chd1 was shown to interact with Rtf1, a component of the Paf1 complex that interacts 
with the RNA Polymerase II and regulates transcription elongation (211). Chd1 has 
been identified as a component of the yeast SAGA/SLIK (Spt, Ada, Gcn5 
acetyltransferase / SAGA-like) complex (212). Murine Chd1 interacts with hormone 
nuclear receptor corepressor (NCoR), thus suggesting a role for mouse Chd1 as a 
transcriptional repressor. Moreover, yeast Chd1 antagonizes the yeast „facilitates 
chromatin transcription‟ complex (yFACT), which contains the SSRP1 homologue 
(Pob3) (213). FACT complex facilitates TATA-Binding Protein (TBP) and TFIIA binding 
to nucleosomal binding sites in addition to its role in transcription elongation.   
The other member of the CHD Subfamily I CHD2 shares ~60% similarity with 
CHD1 at protein level with the least degree of homology at the N and C-termini that lack 





CHD Subfamily II 
CHD subfamily II consists of two proteins: CHD3 and CHD4, also known as Mi-
2α and Mi-2β, respectively. Mi-2 proteins are present in the animal and plant kingdoms, 
but are absent in yeast. CHD3 and CHD4 were initially identified as autoanitgens in the 
connective tissue of patients with the autoimmune disorder dermatomyositis (214). 
Biochemical analysis of Hela cells identified Mi-2α/β as a major component of the 
vertebrate Mi-2/NuRD (Nucleosome remodeling deacetylase) complex, a multi-subunit 
protein complex containing both histone deacetylase activity (HDAC1/2) and ATPase-
dependent nucleosome remodeling activity. In addition to the Mi-2 proteins and 
HDAC1/2 proteins, the NuRD complex contains either one of the metastasis-associated 
proteins (MTA1, 2, 3), methyl CpG-binding domain-containing protein 3 (MBD3), and 
the retinoblastoma-associated proteins 46/48 (RbAp46/48) (214). The NuRD complex 
possesses seemingly contradictory activities in HDAC, which deacetylate histone tails to 
repress transcription, and ATPase nucleosome remodeling activities, typically 
associated with activating transcription. However, the NuRD complex is associated with 
transcriptional repression and can be targeted to different genes depending on the 
identity of the MTA protein (215). MTA1 has been shown to repress estrogen receptor-
associated transcription and interacts directly with ER in breast cancer cell lines and 
affect ER-mediated BRCA1 gene transcription. Meanwhile MTA3 was shown to regulate 
Snail transcription and interact with its promoter in-vivo (215).  
Differently from the CHD subfamily I that possess the C-terminal HMG-1 (Myb-
related) DNA-binding domain, Mi-2 proteins have a plant homeodomain (PHD) as the 
DNA-binding domain located in the N-terminus of the proteins. The PHD domain is 
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homologous to the leukemia associated protein (LAP) and contains a RING domain 
(Cys3-His-Cys4), a Zinc-finger like domain that binds DNA to activate transcription (216). 
However, activation of ATPase activity of Mi-2 proteins is stimulated by binding 
chromatin, not by free DNA or histones (214).  
CHD Subfamily III 
 CHD subfamily III consists of five proteins: CHD5 through CHD9. CHD subfamily 
III proteins have the two chromodomains, ATPase/helicase domain, and the C-terminal 
helicase domain; moreover, they possess additional domains like a paired BRK 
(Brahma and Kismet) domain, a CR domain, SANT-like domains, and a DNA-binding 
domain (217). CHD subfamily III proteins have been identified in higher eukaryotes and 
studied mostly in mammals and to some extent in Drosophila. CHD5 has two PHD Zinc 
finger-like domains and a DEAD-box helicase domain associated with RNA-dependent 
helicase/ATPase activity. Human CHD5 protein is expressed in neural-derived tissues 
and was identified in patients with neuroblastoma (217, 218). CHD5 is located on the 
chromosomal locus 1p36, a region commonly deleted in neural, epithelial and 
hematopoietic cancers (219). CHD5 was proposed to function as a tumor suppressor 
protein because Chd5-compromised cells (thus termed due to rearrangement or 
deletions) had reduced expression of p16Ink4a, p19Arf, and p53. CpG mediated 
hypermethylation of CHD5 promoter was found in human cancers including gastric and 
ovarian cancer, and also in squamous cell carcinoma cell lines (220, 221). 
 CHD6 is a ubiquitously expressed protein and a component of the PRIC complex 
(PPARα-interacting cofactor) through interaction with PPAR protein (222). CHD6 also 
88 
 
interacts with the transcription factor Nrf, which is implicated in cellular respiration 
homeostasis, cell growth and heme biosynthesis (223). Additionally, CHD6 was shown 
to co-localize with active RNA polymerase, but not a strong physical interaction. CHD6 
has a DNA binding domain that has an affinity for A+T rich DNA (AT hook). 
 CHD7 is also a ubiquitously expressed protein first identified as a genetic 
mutation in CHARGE syndrome patients (224). Additional studies using mouse models 
with mutant Chd7 gene phenocopied CHARGE syndrome with mice exhibiting heart 
defects, atresia of the choanae, and prenatal death (225). In a study to analyze CHD7 
chromatin localization in mouse embryonic stem (ES) cells using a ChIP-Seq strategy, 
CHD7 was shown to localize with ES cell master regulators OCT4, SOX2, and NANOG 
(226). Additionally, CHD7 interacts with and co-localizes with P300 binding sites, a 
component of the P300/CBP (CREB-binding protein) which functions as a HAT and a 
known enhancer-binding protein complex.  
 CHD8 was first identified as a protein that interacts with the insulator binding 
protein CTCF at its target site „differentially methylated region‟ (DMR) of H19. siRNA 
mediated CHD8 knockdown abolished CTCF-mediated insulator activity, as the 
expression of the H19 locus gene IGF2 was increased (227). Additionally, knockdown of 
CHD8 affected CpG hypermethylation, histone acetylation, and heterochromatin 
spreading around the CTCF binding sites of BRCA1 and c-Myc genes. Moreover, CHD8 
interacts and negatively regulates β-catenin of the canonical Wnt signaling pathway, as 
shown by increased β-catenin target gene expression in response to loss of CHD8 
(228). In a study of CHD8 function in mice, Chd8−/− embryos die in utero between 
embryonic day E5.5 and E7.5 due to widespread apoptosis (229). Further investigation 
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showed an interaction of CHD8 with the tumor suppressor p53 and histone H1. 
Depletion of CHD8 or histone H1 resulted in p53 activation and apoptosis, and CHD8 
promoted histone H1 binding with p53 promoter to form a trimeric complex and inhibit 
p53-dependent transactivation of its target genes.  
 The last member of CHD subfamily III proteins, CHD9, was first isolated as a 
chromatin-related mesenchymal modulator (CReMM) from mesenchymal stromal cells 
(MSC) (230). Murine CHD9 expression is restricted to marrow stromal progenitor cells  
during the embryonic development of the mouse skeletal system by binding osteocalcin, 
collagen-II, myosin, and CBFA1 promoters which affect tissue specificity (217).  
Chromodomain Helicase DNA Binding Protein 2 (CHD2) 
 CHD2 is the second member of the CHD subfamily I proteins and shares 59% 
homology and 70% identity with CHD1. Human CHD2 is located on chromosome 
15q26.1 and encodes an 1828 amino acids protein with a proposed splice variant of 
1739 AA protein (Ensembl: ENSG00000173575), while the murine CHD2 is located on 
chromosome 7D1 and encodes an 1827 amino acids protein (Ensembl: ENSMUST-
00000169922). CHD2 has two N-terminal chromodomains, a central SNF2-related 
ATPase/helicase domain, a C-terminus helicase domain, a Myb-related DNA binding 
domain, and a C-terminal HMG-I domain (A+T hook). CHD2 is a poorly characterized 
nuclear protein without biochemical analysis of its chromodomains and DNA binding 
domains. The function of CHD2 is predicted from its homologue CHD1 and a few 
reports in the literature. The human CHD2 chromodomain has a 30 fold weaker 
interaction with the H3K4Me3 modified histone than human CHD1 (208). A microarray 
profile study showed that CHD2 was down-regulated in blood cells of urinary bladder 
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cancer patients compared to healthy controls (231). A study utilizing comparative 
genomic hybridization revealed a homozygous deletion at chromosomal locus 15q26.2 
(encodes CHD2 and RGMA) in the Hodgkin‟s lymphoma cell line HDLM2 (232). Two 
recent studies revealed that Chd2 is important for mouse embryo development and 
survival, and Chd2 mutant mice have impaired kidney function (126, 233). Additionally, 
Chd2 mutant mice develop spontaneous lymphomas and lymphoid hyperplasias. Chd2 
mutant mice also exhibit defective hematopoietic SC differentiation and defective DNA 
damage response (126).  
Chd2 mouse models 
In an effort to understand the role CHD2 in mammalian development, Chd2 
deficient mice were generated in our laboratory using the Baygenomics gene trap 
embryonic stem cell resource. The Baygenomics insertional mutagenesis strategy 
involves the use of a gene-trap cassette consisting of a splice-acceptor-βgeo cassette 
(β-galactosidase-neomycin fusion gene) and characterized using 5‟ RACE (123). We 
obtained one of the ES cell clones that had been characterized to have a gene trap 
insertion within the Chd2 gene for analysis of the gene trap insertion site. Using multiple 
intronic forward primers and a gene-trap specific reverse primer for PCR amplifications 
and sequencing, we determined the gene-trap insertion site to be in intron 1 (Figure 17). 
Chd2-targeted ES cells were used for blastocyst injections using the microinjection 
services at the University of Massachusetts Medical School, Worcester. The colonies 
from germline founders were further expanded for the analysis of the mutant offspring. 
This mouse model was termed N-terminal Chd2 mutant and differs from the C-terminal 
mouse model previously generated and characterized (126). The working model for the 
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Baygenomics gene traps encompasses the splicing of the 5‟ splice site of Chd2‟s exon 
1 (encoding 20 amino acids) into the 3‟ splice site in the gene trap (Figure 16). This 
allows for the in-frame fusion of the first two exons of Chd2 to the B-galacotsidase 
neomycin sequence and the expression of this fusion protein. The expression of this 
fusion protein is mandated for the blastocysts to survive neomycin selection. Upon 
efficient splicing of the Chd2 gene into the gene trap, the remainder exons will not be 
translated and thus the wildtype protein will be haplo-insufficient in heterozygous 
progeny and completely lost in nullisomic progeny. 
 
Figure 16.Schematic representation of the Baygenomics gene trap integrated into intron 1 of Chd2 gene. 
The gene trap cassette contains an Engrailed 2 intronic sequence followed by a splice acceptor 




En2: Engrailed 2 intron sequence          SA: Splice Acceptor site 
β-Geo: β-gal-neomycin fusion gene SV40pA: SV40 poly A 
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Figure 17. Schematic representation of the strategy utilized to configure the gene-trap insertion site in 
intron 1 of the Chd2 gene. Chd2 Intron 1 forward primers were designed at 2kB space intervals and 
tested against one gene-trap specific reverse primer in WT and Heterozygous mice. Sequencing of 
the PCR product indicated that the gene trap was integrated within intron 1 (13.9KB from the 
beginning of the intron) of the Chd2 gene. 
 
Materials and Methods 
Reagents and Antibodies 
Cell culture reagents were obtained from the following sources: fetal calf serum and 
Antibiotic-Antimycotic (Gibco, Invitrogen),5-Flurouracil & Doxorubicin (Sigma). 
Antibodies were obtained from the following sources: CHD2 (Dr. Venkatachalam‟s lab, 
University of Tennessee); p53-K382 Acetylated, H3K9 Acetlated, H4K8 Acetylated (Cell 
Signaling Technology, Danvers, MA, USA); Beta-Tubulin (Gentex, Zeeland, MI); Puma ( 
Calbiochem, Gibbstown, NJ); p21, p53 (FL-393X) (Santa Cruz Biotechnology, Santa 
Cruz, CA).   
Western Blot 
HCT116 cells were scraped in phosphate-buffered saline (PBS), pellet at 1‟400 RPM, 
and lysed in BE lysis buffer plus 1mM PMSF (40mM NaCl, 20mM Tris-HCl pH 7.8, 2mM 
MgCl2, 0.5% NP40, Benzonase (Novagen, 250U/mL)). Cell lysates were mixed with 
reducing Laemmli sample buffer, separated on 8% or 12% SDS–polyacrylamide gels 









at room temperature for 2 hours in TBS-Tween (100mM Tris-HCl, 200mM NaCl, 0.1% 
Tween 20) with 5% milk, and incubated with primary antibody overnight at 4oC or at 
room temperature for 2 hours. After washing with TBS-T, membranes were incubated 
with horse radish peroxidase-conjugated secondary antibody for 1 hour at room 
temperature in TBS-T containing 2% milk. Signal was visualized with the Super Signal 
chemiluminescent reagent (Thermo scientific).  
RNA isolation and RT-PCR protocol 
Total RNA was extracted using Trizol according to the manufacturer‟s instructions 
(Invitrogen) from adult thymus (6 weeks of age).  First strand cDNA synthesis was 
performed with 2µg of total RNA (pretreated with RNAse free DNAse) with random 
hexamers and M-MLV reverse transcriptase (Promega) for 1 hour at 42oC followed by 
inactivation of the reverse transcriptase at 700C for 15 minutes. A similar amount (2µg) 
of total RNA (pre-treated with RNAse free DNAse) was subjected to the above 
mentioned conditions in the absence of M-MLV reverse transcriptase. For PCR assays, 
2µl of the reaction mixture (from a total of 40 µl) obtained from the first strand cDNA 
synthesis reaction was used. The PCR conditions were 940C for 2 min, followed by 30 
cycles at 940C for 30 sec, 580C for 30 sec and 720C for 10 sec.  PCR products were 
resolved by agarose gel electrophoresis and stained with ethidium bromide. For 
Chromatin Immunoprecipitation isolated DNA, 2.5µL of DNA eluant were subjected to 
primer specific amplification, and the PCR conditions were 940C for 2 min, followed by 




Quantitative PCR  
The real-time PCRs were performed on a Bio-Rad iQ5 system using TaqMan® Gene 
Expression Assays (Applied Biosystems, Foster City, CA). Gene-specific primers were 
obtained from Applied Biosystems (Mm00519268_m1 for Puma, Mm01197698_m1for 
Beta-Glucuronidase). Puma expression values (Ct-values) were normalized to the mean 
expression value of the housekeeping genes Beta-Glucuronidase to obtain relative 
expression levels using the 2-ΔΔCt. All reactions were performed in triplicate. 
Chromatin Immunoprecipitation 
HCT116 cells were scraped and crosslinked with 1% formealdehyde (Fisher) in ChIP 
Buffer (60mM KCl, 15mM NaCl, 4mM MgCl2, 15mM HEPES pH 7.6, 0.5% Triton X-100, 
10mM Sodium Butyrate) for 20 minutes at room temperature with rotation. For Mouse 
thymocytes: 6 weeks old mice were sacrificed, thymus was isolated and cells were 
strained using a 0.45µM strainer, cells were then crosslinked with 1% Formealdehyde in 
ChIP buffer. Samples were then neutralized with 300mM Glycine for 10 minutes, 
washed twice with ChIP Buffer, and lysed with ChIP LB (140mM NaCl, 15mM HEPES 
pH7.6, 1mM EDTA, 1% Triton X-100, 0.1% Sodium Deoxycholate, 10mM Sodium 
Butyrate, Protease Inhibitors (Roche), 5µM Trichostatin A) for 10 minutes. Samples 
were sonicated to obtain 500-1000BP DNA fragments and then pre-cleared with 
Protein-G agarose beads overnight at 4oC. Pre-cleared samples (1.5mg) were then 
incubated with primary antibody (4µg) for 6 hours at 4oC and then fresh Protein G 
agarose beads were added to samples and rotated overnight at 4oC. The 
Immunoprecipitates were washed successively with low salt buffer (20mM Tris-HCl [pH 
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7.8], 150mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), high salt buffer (20mM 
Tris-HCl [pH 7.8], 500mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), LiCl 
washing buffer (10mM Tris-HCl [pH 7.8], 250mM LiCl, 1% NP40, 1% Sodium 
Deoxycholate, 1mM EDTA), and TE Buffer. DNA-protein complex were eluted with IP 
elution buffer (1% SDS, 0.1M NaHCO3), reversed crosslink by adding 200mM NaCl and 
incubating eluant at 65oC. Protein and RNA was digested by adding Proteinase K and 
RNase A, respectively and DNA was extracted using GeneJET kit (Fermentas, Glen 
Burnie, MD) and eluted with equal volume of nuclease-free water. 
RNA Interference Transfection 
RNAi oligonucleotides were obtained from IDT DNA (F-LUC-Si, CHD2si-2) or 
Dharmacon (CHD2si, used in most experiments) and resuspended in nuclease-free 
water to a concentration of 40µM. HCT116 cells were plated in 60mm-well plates in 
DMEM media containing 10% fetal bovine serum to give 30–50% confluence. 
Transfection of the RNAi oligonucleotides was performed using Trifectin (IDT-DNA) to 
result in a final RNA concentration of 40 nm. The cells were harvested at different time 
points and lysed in BE lysis buffer (above mentioned) for Western blot analysis. siRNA 
sequences were:  
F-Luc si: 5'-rGrCrA rUrArU rCrArA rArGrC rArCrA rUrCrA rGrGrU rCrCA C-3' 
            5'-rGrUrG rGrArC rCrUrG rArUrG rUrGrC rUrUrU rGrArU rArUrG rCrCrU-3' 
CHD2si: 5' rUrUrA rGrArC rArUrU rGrGrG rArUrC rUrUrA rGrGrA rUrUrC rUrUrC 3' 
             5' rArGrA rArUrC rCrUrA rArGrA rUrCrC rCrArA rUrGrU rCrUA A -3' 





4.1. Characterization of N-terminal Chd2 deficient mice. 
The gene-trap in the Chd2 C-terminal model inserts in intron 27, thus retaining a 
substantial portion of the Chd2 protein (translation of the first 1198/1828 amino acids). 
This truncated protein retains all common CHD domains fused to the β-galactosidase-
neomycin gene. This fusion protein may have a dominant negative effect, a gain of 
function effect, or sequester the function of binding proteins necessary to mediate Chd2 
activity. Therefore, we resorted to the Chd2 N-terminal mouse model (Here forth, the 
only model studied) as a better alternative to study Chd2‟s function in mammalian 
development, DNA damage response, and tumorogenesis. We analyzed the post-natal 
lethality of Chd2 mutant mice. Analysis of Heterozygous matings at weaning (day 21) 
shows a 27% survival of the null offspring, which indicates lethality of the Chd2 mutant 
mice. The mutant offspring that survived beyond the perinatal stage did not show any 
overt developmental abnormalities. However, after 5–12 months of age, the 
heterozygous mice began to exhibit weight loss, lordokyphosis (hunch-back spine) and 
loss of vitality. Survival analysis showed drastic reduction in the lifespan of the Chd2 




Figure 18. Chd2 deficiency leads to reduced lifespan in mice. Kaplan-Meier survival curves of Chd2 
mutant and wild-type littermates (n=30). The percentages of survival are plotted as a function of age 
in weeks.  Animals were monitored for tumors, morbidity, or spontaneous death over a period of 
120 weeks. Of the 30 animals analyzed for each group, all the heterozygous mutants have died in 
comparison to 10 for the wild-type controls. The median lifespan of the Chd2 +/- mice was 59.35 
weeks in comparison to 91.3 weeks in the wild type littermate controls. All mice were of mixed 
inbred C57BL/6X129/Sv background.   
 
 Histological examination of organs harvested from morbid mice showed that a 
majority of the mice were succumbing to splenic or thymic lymphomas or lymphoid 
hyperplasias with a fraction of adenomas and sarcomas (Table ). The earliest incidence 
of lymphomas in the mutant mice was at 26 weeks of age. 53% of the heterozygous 
mutants (16/30) exhibited spontaneous tumor formation. In comparison, only 25% of 
wild-type mice were diagnosed with a tumor during the analysis period (4/12). Wild-type 
mice also develop lymphomas as a function of age, and such tumors account for about 
5–20% incidence as reported for mice of various genetic backgrounds by others. 
Histological examination of organs also revealed Glomerulo-nephoropathies and 
inflammation of the heart or arteries in a minority of the animals as well as Extra 
Medullary Hematopoiesis (EMH) in 57% of the animals examined. 
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Table 3. Distribution of pathological conditions in Chd2 deficient (N-terminal mutant) mice.  Tissues from 
a total of 30 mice (Chd2+/-) were analyzed to determine the reasons for morbidity.  Hearts were 
examined for 8 mice.  To avoid over-estimation of lymphoid hyperplasias, animals exhibiting 
lymphomas as well as lymphoid hyperplasias (in other organs) were categorized under 
lymphomas. *15 out of 17 animals diagnosed with EMH exhibited either lymphoid hyperplasia or 
lymphoma. ** Both the animals exhibiting nephropathy were diagnosed with either lymphoid 
hyperplasia or lymphoma. ***The animal diagnosed with heart inflammation exhibited either 
lymphoid hyperplasia. ****Three animals were diagnosed with bronchoalveolar adenoma and two 
were diagnosed with sarcomas.  
Lymphoma 53%  (16 of 30) 
Lymphoid hyperplasia 36.6%  (11 of 30) 
Extra Medullary Hematopoiesis* (EMH) 56.6%  (17 of 30) 
Glomerulo-nephropathy** 10%  (2 of 19) 
Inflammation of heart/artery*** 11%  (1 of 9) 
Other cancers**** 16.6%    (5 of 30) 
 
 
Since histological analysis of Chd2 heterozygous mice revealed thymic 
lymphomas and thymic hyperplasias, we wanted to test whether Chd2 plays its greatest 
role specifically in the thymus of mice. For that, we crossed Chd2 heterozygous males 
with Lck-Cre transgenic founder female mice expressing Cre recombinase exclusively in 
thymus. This leads to excision of the splice-acceptor site of the gene trap, thus 
bypassing it and leading to wildtype expression of Chd2 in the thymus only (termed LY-
Cre). Chd2 expression in the thymus restored normal life span of heterozygous mice to 
that of wild type mice. Median lifespan for LY-Cre heterozygous mice was 102 weeks 
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(n=8) compared to a median lifespan of 59 weeks for Chd2 heterozygous mice (Figure 
19).  
 
Figure 19. Restoration of CHD2 expression in thymus restores normal life span of CHD2 heterozygous 
mice. Kaplan-Meier survival curves of Chd2 mutant and wild-type littermates (n=8). The 
percentages of survival are plotted as a function of age in weeks.  Animals were monitored for 
tumors, morbidity, or spontaneous death over a period of 120 weeks. The median lifespan of the 
Chd2 +/- mice was 59.35 weeks in comparison to 102 weeks in the LY Cre Het mice. All mice were 
of mixed inbred C57BL/6X129/Sv background.   
 
To determine the mechanistic role of Chd2 in tumorogenesis, we tested the 
fidelity of the cell cycle progression in wildtype and Chd2 mutant MEFs. Incorporation of 
the thymidine analog, Bromodeoxyuridine (BrdU), indicates cell proliferation. Cells that 
are treated with X-ray radiation arrest at the G1/S and G2/M boundaries and therefore 
don‟t incorporate BrdU. Flow cytometry analysis indicates that Chd2+/m and Chd2m/m 
keep incorporating BrdU 16 hours after treatment with X-ray radiation (Figure 20). 
Furthermore, Chd2+/m and Chd2m/m do not arrest at the G2/M boundary either. This is 
indicative of a cell cycle arrest deficiency which can be caused by the deregulation of 





Figure 20. Effects of Chd2 on Cell-cycle Arrest. DNA damage induces the cell-cycle inhibitor p21 
causing arrest in the G1/S  and G2/M phase. Wildtype cells exhibit cell-division arrest after 
treatment with 4Gy X-Ray. Chd2 heterozygous and nullizygous MEFs exhibit a diminished G2/M 
arrest and increased S phase synthesis.  
4.2. Chd2 deficient thymocytes exhibit deficient Puma response.  
Since many of the Chd2 heterozygous mice were succumbing to lymphomas and 
lymphoid hyperplasias and hematopoietic deficiencies, we tested the ability of Chd2 
mutant animals to undergo apoptosis. We picked the p53-upregulated modulator of 
apoptosis (Puma) as a candidate gene to test its induction in wildtype and Chd2 mutant 
thymocytes. RT-PCR analysis showed a severe deficiency in Chd2+/m and Chd2m/m 
thymocytes‟ ability to induce Puma after DNA damage (Figure 21). Q-PCR analysis 
further confirmed our initial findings where Puma was 27 folds higher in treated wildtype 
thymocytes over the untreated control (Figure 22). Meanwhile, Puma was only 2.5 and 
1.3 folds higher in treated Chd2+/m and Chd2m/m thymocytes over the untreated 





















































Figure 21. Expression of PUMA in Chd2 Thymocytes.  Chd2 thymus were isolated and total RNA was 
harvested 3H after 6Gy X-ray treatment. RT-PCR analysis show no induction of the p53-
















Figure 22. Real-Time analysis of PUMA levels in Chd2 thymocytes. Wildtype Thymocytes show  a 27 
fold induction of Puma three hours after treatment with 6Gy X-ray. Chd2 heterozygous and 
nullisomic thymocytes exhibit a lack of induction after DNA damage. B-Glucuronidase (GusB) was 






















4.3. CHD2 deficient cells exhibit reduced PUMA induction 
RNA interference was effective in reducing CHD2 protein levels in HCT116 cells. 
CHD2 is not induced after treatment of cells with the thymidylate synthase inhibitor 5-
Flurouracil (Figure 23). Chd2 deficiency did not have an effect on the lysine 382 
acetylation of p53 after 5FU treatment. However, Puma levels were greatly reduced in 
CHD2 deficient cells compared to controls (Figure 23). Additionally, p21 levels were also 
reduced in CHD2 deficient cells, indicating an insufficient induction of these p53 
regulated genes.  Beta-tubulin indicates equal loading control of cell lysates (Figure 23). 
Since CHD2 appears to play a role in transcriptional upregulation of Puma, we wanted 
to test whether CHD2 deficiency affects histone tail markers associated with 
transcriptional activation. Acetylation of lysine 9 of Histone 3 (H3K9Ac) and acetylation 
of lysine 8 of Histone 4 (H4K8Ac) are well known markers of active transcription. Global 
acetylation of these two histones was reduced in untreated CHD2-deficient cells 
compared to wild type cells (Figure 24). 5FU treated CHD2-deficient cells showed a 
greater reduction of each of these marks compared to controls, thus further indicating a 
deficiency in histone acetylation in CHD2-deficient cells. However, although PUMA was 
not being induced, apoptosis was still proficient as indicated by cleavage of poly ADP 
ribose polymerase (Figure 24). Same results were obtained using a second set of CHD2 





Figure 23. Western blot analysis of CHD2 deficient DNA-damage response in HCT116 cells. RNAi was used 
to attenuate CHD2 protein levels. P53 acetylation at lysine 382 was not affected by CHD2 knockdown, yet levels 
of the p53 target gene Puma were reduced in CHD2-deficient cells compared to control (F-Luc). P21, another p53 









Figure 24. Western blot analysis of CHD2 deficient DNA-damage response in HCT116 cells. RNAi was 
used to attenuate CHD2 protein levels. Levels of histone H3 (Lys9 acetylated) and histone H4 
(Lys8 acetylated) were reduced in CHD2-deficient cells compared to control (F-Luc). The 
apoptosis associated protein PARP levels remained similar in 5FU treated cells in both control 
and CHD2-deficient cells. Beta-Tubulin shows loading control 
4.4. CHD2 localizes to Puma in mouse thymocytes.  
Based on these findings, we wanted to determine whether Chd2 plays a role in 
the induction of Puma. We utilized chromatin immunoprecipitation (ChIP) to determine 
whether CHD2 binds to the Puma promoter and the p53 response element there. Our 
results initially indicated that Chd2 binds to the Puma promoter in wildtype thymocytes 
(primers designed to amplify p53 RE located in Intron 1 of the Puma promoter) 
specifically after DNA damage (Figure 25). Further experiments showed that Chd2 is 
enriched at the Puma promoter after DNA damage. Moreover, we tested a region 1.5KB 
upstream of the Puma promoter as an additional control and were able to amplify that 
region, which could indicate the spreading of Chd2 throughout the region (Figure 26). 
However, CHD2 didn‟t localize to an unrelated gene HGPRT. We then tested whether 
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Chd2 plays a role in the recruitment of p53 to its response element on the Puma 
promoter. DNA analysis indicates that p53 is recruited to its cognate region sufficiently 
in wildtype and Chd2 mutant thymocytes; furthermore, p53 is enriched at its Puma RE 
after DNA damage, which is consistent with previous studies (Figure 27). 
 
 
Figure 25. Chromatin immunoprecipitation (ChIP) on wildtype thymocytes. DNA analysis on Chd2 IP 





Figure 26. Chromatin immunoprecipitation (ChIP) on wildtype thymocytes. DNA analysis on Chd2 IP 
shows localization to the Puma promoter. Lack of amplification of the HGPRT region indicates 
specificity of Chd2 IP. 10% Input shows total lysate control. Upstream indicates the 1.5KB region 















Figure 27. Chromatin Immunoprecipitation analysis on Chd2 Thymocytes. DNA analysis on Chd2 IP 
shows localization to the PUMA promoter after DNA damage. p53 IP on WT and Chd2 nullisomic 
thymocytes shows no role for Chd2 in localizing p53 to the PUMA promoter. 10% Input shows 
total lysate control. 
4.5. CHD2 localizes to Puma in p53-dependent manner in HCT116 cells. 
In HCT116 wild type cells, CHD2 localizes to the p53 response element of the 
Puma promoter before DNA damage, but is enriched there after DNA damage (Figure 
28Figure 29). Moreover, Chd2 localizes to the p53 response element of the Puma 
promoter in the thymocytes of wildtype mice. CHD2 localizes to other regions within the 
Puma locus including Intron 3, which has been reported to be enriched in trimethylated 
H3K9 histones and occupied by the insulator protein CTCF (234). Additionally CHD2 is 
slightly enriched in the 5KB region upstream of the PUMA promoter after DNA damage, 
indicating its ability to spread beyond the promoter (Figure 30). However, CHD2 doesn‟t 
localize to the Beta-Glucuronidase promoter before or after DNA damage (Figure 31). 
The tumor suppressor protein p53 also is enriched at the PUMA promoter, which has 
Control 
WT Thymus 





been established before. This enrichment of CHD2 in a manner similar to p53 at the 
PUMA promoter led us to test whether p53 and CHD2 are co-dependent on each other 
to be recruited to the PUMA promoter. For, we tested the localization of CHD2 to PUMA 
promoter in HCT116 Null cells which lack p53. The localization of CHD2 to the Puma 
promoter was reduced as indicated by the band intensity (Figure 29). Additionally, the 
localization of CHD2 to the 5KB region upstream of PUMA promoter was greatly 
increased after DNA damage in the p53 deficient cells. Moreover, CHD2 appears to 
localize to the Beta-Glucuronidase promoter after DNA damage in p53 deficient cells, 
indicating a possible role for p53 in guiding the localization of CHD2 (Figure 31). We 
then tested whether CHD2 deficiency affects p53 localization to its cognate response 
element in the PUMA promoter. P53 was enriched after DNA damage at the PUMA 
promoter in CHD2 deficient cells but at lower intensity compared to wild type cells 
(Figure 29). H3K9Ac markers enrichment at the Puma promoter appears to remain 
unchanged in wild-type and CHD2-deficient cells (Figure 32). Although we have shown 
that CHD2 deficiency reduces global acetylation, especially after DNA damage, it‟s 
possible that Puma acetylation is not affected in this case, or that we acetylation of 
Puma remains constant, while only CTCF mediates transcription of exon 3 to form the 




Figure 28. Chromatin Immunoprecipitation analysis of CHD2 localization to p53 response element in 
Puma. DNA analysis on Chd2 IP shows localization and enrichment to the PUMA promoter after 
DNA damage. CHD2 localization is reduced in HCT116 p53-/- cells as shown by reduced intensity 












Figure 29. ChIP analysis of p53 localization to its response element in Puma. DNA analysis on p53 IP 
shows localization and enrichment to the PUMA promoter after DNA damage. P53 localization is 
reduced in HCT116 treated with CHD2-specific siRNA cells as shown by reduced intensity of 






Figure 30. ChIP analysis of CHD2 localization to a 5KB region upstream of Puma promoter. DNA analysis 
on Chd2 IP shows localization of CHD2 to the upstream region of the PUMA promoter after DNA 
damage. CHD2 localization is greater in HCT116 p53-/- cells as shown by increased intensity of 
bands, possibly indicating a role for p53 in CHD2 localization. 1% Input shows equal total lysate 






Figure 31. ChIP analysis of CHD2 localization to an unrelated Beta-Glucuronidase promoter. DNA 
analysis on Chd2 IP shows no localization of CHD2 to the Gus-B promoter in HCT116 cells. CHD2 
localization to this region is seen in HCT116 p53-/- cells as shown by presence of bands, possibly 
indicating a role for p53 in CHD2 localization. 1% Input shows equal total lysate control, and IgG 






Figure 32. ChIP analysis of Acetylated histone H3 (Lys9) localization to Puma promoter. DNA 
analysis on H3K9Ac IP shows similar levels of localization before and after DNA damage at the 
Puma promoter and in wild type and CHD2-deficient cells. 1% Input shows equal total lysate 





Our results suggest an indispensible role for CHD2 in preventing tumorogenesis 
and inducing Puma after DNA damage. Previous work in our laboratory had shown that 
Chd2 mutant mice succumb to lymphomas and have a deficient DNA damage response 
(126). However, our previous mouse model (C-terminal) expresses the first 27 exons of 
Chd2, which encode for the chromodomain, SNF2-related helicase domain, C-terminal 
helicase domain, fused to the neomycin-β-gal gene. This can potentially create a 
dominant negative protein that can interact with wild type Chd2. Our current model (N-
terminal) possesses the gene-trap after exon 1 (20 amino acids) of Chd2, thus creating 
a superior hypomorphic model to study the role of Chd2. Similar to the C-terminal 
mouse model, N-terminal mutant mice also exhibit reduced lifespan and spontaneous 
lymphomas. However, the spectrum of tumors expands to include sarcomas and 
adenomas (16.6% of mice), which was absent from the C-terminal model. Additionally, 
restoration of Chd2 expression in the thymus of mutant mice restores their lifespan to 
that of wild type littermates, thus suggesting that Chd2 plays its greatest role in the 
thymus. We suspected Chd2 to play a role in DNA damage repair pathways and wanted 
to test the effect of Chd2 deficiency on the induction of the cell-cycle progression gene 
(p21) and apoptosis related genes (Puma, Noxa, Bax). Indeed, Puma induction both in 
mouse thymus was reduced after X-ray irradiation in Chd2 deficient cells, indicating a 
role for Chd2 as a transcriptional regulator of Puma induction.  Because of the time 
consuming nature of animal work and lack of reliable mouse specific antibodies, we 
wanted to test the effect of CHD2 deficiency on PUMA induction in HCT116 cells. 
HCT116 cells are epithelial colon cancer cells that are capable of undergoing apoptosis 
when chemically stressed. Another advantage to using HCT116 cells is they are 
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available in both wild type and p53 null lines. Therefore, we can test the effect of p53 on 
a proteins function while maintaining every other pathway in the cell line. We tested 
multiple chemical stressors in HCT116 cells to check the best induction of PUMA, and 
concluded that 5-flurouracil is the best compound to induce PUMA. CHD2 deficient cells 
exhibited reduced PUMA induction after treatment with 5FU. This pattern is similar to 
the reduced Puma induction in Chd2 mutant mouse thymocytes. Interestingly, it 
appears that apoptosis is not affected by the lack of PUMA induction as PARP cleavage 
is similar in both control and CHD2-deficient cells treated with 5-FU. Since apoptosis is 
induced by p53-dependent and p53-independent pathways (TNF-α, Fas- pathways), an 
alternative pathway can possibly trigger apoptosis in the absence of PUMA induction 
after DNA damage. 
P21, another p53 target, was induced in CHD2 deficient cells after DNA damage 
but a lower level than control cells, possibly indicating a role for CHD2 in the induction 
of p53 target genes. In previous work, CHD8 was shown to affect the acetylation of p53 
and the induction of its downstream targets; therefore, we wanted to test whether CHD2 
deficiency affects p53 acetylation to possibly designate a mechanism of action for 
CHD2 (229). Acetylation of p53 at lysine 382 of its C-terminal regulatory region has 
been shown to enhance p53‟s activity as a transcription factor, allowing p53 to bind its 
RE with a greater affinity. CHD2 deficiency did not affect p53 acetylation at Lysine 382 
after 5FU treatment, thus indicating a different mechanism of action for CHD2 on 
transcription activation. We next looked at CHD2‟s affect on Histone acetylation 
because CHD1 has been shown to be a component of the SAGA histone 
acetyltransferase complex (212). H3K9 and H4K8 acetylation are well known 
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transcriptional activation markers (235). Histone acetylation at majority of genome is 
reduced after DNA damage to allow the cell to resolve the damaged DNA before 
continuing through the cell cycle. CHD2 deficient cells exhibit global reduction in H3K9 
and H4K8 acetylation when comparing untreated cells (No DNA damage). After DNA 
damage, H3K9 and H4K8 acetylation is reduced in control cells but is almost 
undetectable in CHD2 deficient cells. This indicates a role for CHD2 in histone 
acetylation and possibly preludes a mechanism for the lack of PUMA induction after 
DNA damage. 
We further verified a role for CHD2 in PUMA induction by checking CHD2 
localization to the Puma locus using Chromatin Immunoprecipitation. DNA eluted from 
CHD2 ChIP was amplified using specific primers to test the p53 response element of 
the Puma promoter, a 5KB region upstream of this response element, a region of Intron 
3 of Puma locus, and an unrelated Beta-Glucuronidase promoter (GusB). The 5KB 
region and the Intron 3 test whether CHD2 spreads beyond the promoter of Puma, while 
the GusB promoter works as a control of a housekeeping gene. CHD2 is enriched at the 
p53 response element after DNA damage, but this enrichment is slightly reduced in p53 
deficient HCT116 cells. CHD2 spreads to the 5KB region upstream of Puma promoter 
and to Intron 3 after DNA damage, showing that it spreads all along a locus to remodel 
chromatin. CHD2 is present in higher levels at the 5KB upstream region and is reduced 
at the Puma promoter in p53 deficient HCT116 cells after DNA damage. This points to a 
role for p53 in guiding CHD2 binding on the genome or at least laying the groundwork 
for CHD2 binding through its chromodomain or its A+T hook DNA binding domain. Also, 
CHD2 binds to the GusB promoter in p53 deficient cells after DNA damage; this is not 
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seen in wild type cells and further leads to a role for p53 in guiding CHD2 binding. 
CHD2 deficiency also slightly reduces p53 localization to its response element after 
DNA damage. This could be due to reduced global acetylation in CHD2 deficient cells, 
which makes the chromatin more compact and less accessible to transcription factors. 
We also tested whether CHD2 binds to p53 RE at the CDKN1A locus (p21 locus) and 
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